

FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE



INFORMAZIONI PERSONALI

Nome **CAPUTI ACHILLE PATRIZIO**  
Indirizzo **VIA PRINCIPESSA MAFALDA, 44 - 98121 MESSINA (ITALY)**  
Telefono **335-7906269**

E-mail [caputi@tim.it](mailto:caputi@tim.it)  
[caputi.ap@gmail.com](mailto:caputi.ap@gmail.com)

Nazionalità Italiana  
Data di nascita 17/03/1946 – ASMARA (ERITREA)

ESPERIENZA LAVORATIVA

- **1971-78** Assistente Ordinario di Farmacologia  
• Tipo di azienda o settore Facoltà di Medicina, Università di Napoli.
- **1978-80** Professore Incaricato di Farmacologia  
• Tipo di azienda o settore Facoltà di Scienze Biologiche, Università di Napoli.
- **Dal 1980 al 30/09/2016** Professore Ordinario di Farmacologia  
• Tipo di azienda o settore Facoltà di Medicina e Chirurgia, Università di Messina
- Dall'1/10/2016** Consulente privato in ambito farmaceutico
- Dal 2019** **Professore Emerito di Farmacologia, Università di Messina**

ISTRUZIONE E FORMAZIONE

- **1970-71** Laurea in Medicina e Chirurgia, Università di Napoli (magna cum laude)  
• Nome e tipo di istituto di istruzione o formazione Corso di Laurea in Medicina e Chirurgia, Facoltà di Medicina e Chirurgia, Università di Napoli
- Qualifica conseguita Medico Chirurgo
- **1977** Department of Pharmacology, University of Pennsylvania, Philadelphia PA., U.S.A  
(prof. Domingo M. Aviado)
- **1978-80** Department of Pharmacology, New Jersey College of Medicine and Dentistry, Newark, N.J., U.S.A. (Dr. Henry E. Brezenoff)

## CAPACITÀ E COMPETENZE PERSONALI

*Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.*

PRIMA LINGUA

ITALIANO

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

INGLESE

Eccellente

Eccellente

Buona

## CAPACITÀ E COMPETENZE RELAZIONALI

*Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.*

- Docente Universitario
- Relatore/moderatore a congressi nazionali ed internazionali
- Relatore in master, corsi di aggiornamento, scuole di specializzazione e corsi ECM per tutte le professioni sanitarie.
- Responsabile scientifico del sito [www.farmacovigilanzasif.org](http://www.farmacovigilanzasif.org)
- Responsabile di diversi progetti a carattere scientifico-divulgativo

## CAPACITÀ E COMPETENZE ORGANIZZATIVE

*Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.*

**Da ottobre 2016:** cessazione dell'attività universitaria per raggiunti limiti di età.  
Consulente privato

**Ottobre 2011 - ottobre 2012:** Direttore Dipartimento Clinico e Sperimentale di Medicina e Farmacologia

**Luglio 2011 - ottobre 2011:** Direttore (in qualità di Decano) Dipartimento Clinico e Sperimentale di Medicina e Farmacologia

**2003-2009:** Direttore del Dipartimento Clinico e Sperimentale di Medicina e Farmacologia

**1983-2000:** Direttore Istituto di Farmacologia

**1991-2003:** Direttore Scuola di Specializzazione in Farmacologia

**1991-2003:** Direttore Scuola di Specializzazione in Tossicologia Medica

**1991-2011:** Coordinatore del dottorato di ricerca in Medicina Sperimentale.

**1985-90:** Presidente Consiglio Corso di Laurea in Odontoiatria e Protesi Dentaria.

**Dal 2012 al 30/09/2016:** Direttore U.O.S.D. di Farmacologia Clinica.

**2000-2002:** Direttore U.O. di Farmacologia Clinica.

**1983-1999:** Primario Servizio di Farmacologia Clinica, Farmacovigilanza e Farmecoepidemiologia

**1991-94:** Coordinatore del "Laboratorio Centralizzato Analisi" del Policlinico

## Società Italiana di Farmacologia

Presidente (2007-2009)

Presidente Eletto (2005-2007)

Coordinatore Nazionale Sezione di Farmacologia Clinica dal 1997 al 2001

Membro Consiglio Direttivo 1986-90

## Società Italiana di Tossicologia

Vicepresidente dal 1996 al 2000

Membro Consiglio Direttivo dal 1992 al 1996

## AIFA

Fino al 2012 Componente sottocommissione farmacovigilanza

Componente del Geriatric Ageing Group

**Regione Sicilia**

Componente della Commissione del Prontuario Terapeutico Provinciale, Messina

Responsabile del Centro Regionale per la segnalazione spontanea delle sospette reazioni avverse da farmaci (fino al 30/09/2016)

Componente della Commissione del Prontuario Terapeutico Ospedaliero-Territoriale della Regione Siciliana (fino ad ottobre 2015)

**Regione Basilicata**

Gennaio 2015 - luglio 2016: Presidente Fondazione Basilicata Ricerca Biomedica (BRB)

CAPACITÀ E COMPETENZE  
TECNICHE  
*Con computer, attrezzature specifiche,  
macchinari, ecc.*

Buona conoscenza dei sistemi operativi Windows 98,2000,XP e dei seguenti programmi: Office 2000-XP, Internet Browsers. Buone capacità di ricerca di informazioni, documenti, articoli scientifici attraverso l'utilizzo dei più importanti siti-web in campo medico.

PATENTE O PATENTI

B

**ULTERIORI INFORMAZIONI**

**Argomenti di ricerca.**

Farmacologia cardiovascolare, con particolare riferimento alle sindromi di ischemia e riperfusione

Farmacovigilanza, farmacoutilizzazione e farmacoepidemiologia con particolare riferimento alle banche dati (real world evidence).

**Publicazioni scientifiche (vedi allegato)**

Autore/coautore di 6 libri e di decine di capitoli su testi di farmacologia di altri autori

Pubblicazione di oltre 420 lavori su riviste scientifiche riportate su MEDLINE.

Dichiaro che le informazioni riportate nel presente Curriculum Vitae sono esatte e veritiere.

Autorizzo al trattamento dei miei dati personali ai sensi del Regolamento UE 2016/679.

25/03/2022

Achille P. Caputi

**Elenco lavori in extenso pubblicati su riviste con IF e Comitato di Referee**

1. **Caputi AP**, Navarra P. Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. Review. *Curr Opin Pharmacol.* 2020; 51:93-101.
2. Polimeni G, Trifirò G, Ingrassiotta Y, **Caputi AP**. The advent of biosimilars for the treatment of diabetes: current status and future directions. *Acta Diabetol.* 2015; 52:423-31.
3. Calapai G, Miroddi M, Minciullo PL, **Caputi AP**, Gangemi S, Schmidt RJ. Contact dermatitis as an adverse reaction to some topically used European herbal medicinal products - part 1: *Achillea millefolium-Curcuma longa*. *Contact Dermatitis.* 2014; 71:1-12.
4. Ingrassiotta Y, Belleudi V, Trotta F, Addis A, Fontana A, Chinellato A, Ientile V, Tari DU, Roberto G, Pastorello M, Scondotto S, Cananzi P, **Caputi AP**, Davoli M, Rossi M, Trifirò G; Italian Biosimilars Network (I-BioNetwork). In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. *BioDrugs.* 2020; 34:55-64.
5. Biffi A, Scotti L, Rea F, Lucenteforte E, Chinellato A, Vetrano DL, Vitale C, Agabiti N, Sultana J, Roberto G, Mugelli A, **Caputi AP**, Corrao G; Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Adherence to Antidepressants and Mortality in Elderly Patients with Cardiovascular Disease. *Clin Drug Investig.* 2018 38:593-602.
6. Roberto G, Bartolini C, Rea F, Onder G, Vitale C, Trifirò G, Kirchmayer U, Chinellato A, Lucenteforte E, Corrao G, Mugelli A, Lapi F, **Caputi AP**, Gini R; Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease. *Eur J Clin Pharmacol.* 2018; 74:637-643.
7. Ghirardi A, Scotti L, Zambon A, Della Vedova G, Cavalieri D, Lapi F, Cipriani F, **Caputi AP**, Vaccheri A, Gregori D, Gesuita R, Vestri A, Staniscia T, Mazzaglia G, Corrao G; Risk of severe upper gastrointestinal complications among oral bisphosphonate users. *PLoS One.* 201; 8:e 73159.
8. Ferrara R, Ientile V, Piccinni C, Pasqua A, Pecchioli S, Fontana A, Alecci U, Scoglio R, Magliozzo F, Torrisi SE, Vancheri C, Vitulo P, Fantaci G, Ferrajolo C, Cazzola M, Cricelli C, **Caputi AP**, Trifirò G. Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. *NPJ Prim Care Respir Med.* 2018; ;28(1):10
9. Mennini FS, Sciattella P, Marcellusi A, Marcobelli A, Russo A, **Caputi AP**. Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline. *Expert Rev Pharmacoecon Outcomes Res.* 2017; 17:503-510.
10. Mannucci C, Navarra M, Calzavara E, **Caputi AP**, Calapai G. Serotonin involvement in *Rhodiola rosea* attenuation of nicotine withdrawal signs in rats. *Phytomedicine.* 2012; 19:1117-24.
11. Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea G, Cricelli C, **Caputi AP**, Mazzaglia G. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. *Ann Rheum Dis.* 2013; 72:694-700.

12. Belleudi V, Trotta F, Addis A, Ingrasciotta Y, Ientile V, Tari M, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, **Caputi AP**, Trifirò G; Italian Biosimilar Network (ItaBioNet). Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. *Drug Saf.* 2019; 42:1437-1447
13. Rea F, Calusi G, Franchi M, Vetrano DL, Roberto G, Bonassi S, Kirchmayer U, Chinellato A, Bettiol A, Sultana J, Mugelli A, **Caputi AP**, Corrao G; I-GrADE Investigators. Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation. *Drugs Aging.* 2018; 35:1099-1108.
14. Trifirò G, Parrino F, Pizzimenti V, Giorgianni F, Sultana J, Muscianisi M, Troncone C, Tari DU, Arcoraci V, Santoro D, Russo G, Lacava V, **Caputi AP**. The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy. *Clin Drug Investig.* 2016; 36:203-12
15. Trifirò G, Tillati S, Spina E, Ferrajolo C, Alacqua M, Aguglia E, Rizzi L, **Caputi AP**, Cricelli C, Samani F. A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. *Eur J Clin Pharmacol.* 2013; 69:227-36.
16. Cutroneo PM, Italiano D, Trifirò G, Tortorella G, Russo A, Isola S, **Caputi AP**, Spina E. Acute cerebellar ataxia following meningococcal group C conjugate vaccination. *J Child Neurol.* 2014; 29:128-30.
17. Ghirardi A, Scotti L, Vedova GD, D'Oro LC, Lapi F, Cipriani F, **Caputi AP**, Vaccheri A, Gregori D, Gesuita R, Vestri A, Staniscia T, Mazzaglia G, Corrao G; AIFA-BEST Investigators. Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: a nested case-control study. *BMC Gastroenterol.* 2014; 7:14:5.
18. Ghirardi A, Di Bari M, Zambon A, Scotti L, Della Vedova G, Lapi F, Cipriani F, **Caputi AP**, Vaccheri A, Gregori D, Gesuita R, Vestri A, Staniscia T, Mazzaglia G, Corrao G; BEST investigators. Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study. *Eur J Clin Pharmacol.* 2014; 70:1129-37.
19. Salvo F, Miroddi M, Alibrandi A, Calapai F, Cafeo V, Mancari F, Gangemi S, **Caputi AP**, Calapai G. Attitudes and opinion about adverse drug events of women living in a city of south Italy. *Pharmacology.* 2013; 91:173-7.
20. Mazzaglia G, Piccinni C, Filippi A, Sini G, Lapi F, Sessa E, Cricelli I, Cutroneo P, Trifirò G, Cricelli C, **Caputi AP**. Effects of a computerized decision support system in improving pharmacological management in high-risk cardiovascular patients: A cluster-randomized open-label controlled trial. *Health Informatics J.* 2016; 22:232-47.
21. Ingrasciotta Y, Giorgianni F, Marciandò I, Bolcato J, Pirolò R, Chinellato A, Ientile V, Santoro D, Genazzani AA, Alibrandi A, Fontana A, **Caputi AP**, Trifirò G. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. *PLoS One.* 2016; 11:e0155805.
22. Paoloni M, Bernetti A, Belelli A, Brignoli O, Buoso S, **Caputi AP**, Catani F, Coclite D, Fini M, Mantovani L, Migliore A, Napoletano A, Viora U, Santilli V. Appropriateness of clinical and organizational criteria for intra-articular injection therapies in osteoarthritis. A Delphi method consensus initiative among experts in Italy. *Ann Ist Super Sanita.* 2015; 51:131-8.
23. Rafaniello C, Arcoraci V, Ferrajolo C, Sportiello L, Sullo MG, Giorgianni F, Trifirò G, Tari M, **Caputi AP**, Rossi F, Esposito K, Giugliano D, Capuano A. Trends in the prescription of antidiabetic medications from

2009 to 2012 in a general practice of Southern Italy: a population-based study. *Diabetes Res Clin Pract.* 2015; 108:157-63.

24. Marcianò I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Di Giorgio A, Manna S, Ientile V, Gini R, Santarpia M, Genazzani AA, Uomo I, Pastorello M, Pollina Addario SW, Scondotto S, Cananzi P, Da Cas R, Traversa G, Rossi M, Sottosanti L, **Caputi AP**, Trifirò G. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014. *BioDrugs.* 2016; 30:295-306.

25. Calapai G, Imbesi S, Cafeo V, Ventura Spagnolo E, Minciullo PL, **Caputi AP**, Gangemi S, Milone L. Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report. *J Clin Pharm Ther.* 2013; 38:337-8.

26. Minutoli L, Antonuccio P, Squadrito F, Bitto A, Nicotina PA, Fazzari C, Polito F, Marini H, Bonvissuto G, Arena S, Morgia G, Romeo C, **Caputi AP**, Altavilla D. Effects of polydeoxyribonucleotide on the histological damage and the altered spermatogenesis induced by testicular ischaemia and reperfusion in rats. *Int J Androl.* 2012; 35:133-44.

27. Lapi F, Cipriani F, **Caputi AP**, Corrao G, Vaccheri A, Sturkenboom MC, Di Bari M, Gregori D, Carle F, Staniscia T, Vestri A, Brandi M, Fusco V, Campisi G, Mazzaglia G; Bisphosphonates Efficacy-Safety Tradeoff (BEST) study group. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. *Osteoporos Int.* 2013; 24:697-705.

28. Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, **Caputi AP**, Trifirò G. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013. *BioDrugs.* 2015; 4:275-84.

29. Loiacono C, Sgroi C, Coppolino S, Cannata A, Ferrara R, Arcoraci V, Cananzi P, Savica V, Schuemie M, **Caputi AP**, Trifirò G. How much are biosimilars used in southern Italy? A retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011. *BioDrugs.* 2012; 26:113-20.

30. Trifirò G, Fatuzzo PM, Ientile V, Pizzimenti V, Ferrajolo C, Santoro D, Camacho N, Van Rosmalen J, D'Addetta G, Lanati P, **Caputi AP**, Catinello G, Savica V. Expert opinion of nephrologists about the effectiveness of low-protein diet in different stages of chronic kidney disease (CKD). *Int J Food Sci Nutr.* 2014; 65:1027-32.

31. Cutroneo PM, Isgrò V, Russo A, Ientile V, Sottosanti L, Pimpinella G, Conforti A, Moretti U, **Caputi AP**, Trifirò G. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database. *Drug Saf.* 2014; 37:961-70.

32. Vetrano DL, La Carpia D, Grande G, Casucci P, Bacelli T, Bernabei R, Onder G; **Caputi AP** Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE). Anticholinergic Medication Burden and 5-Year Risk of Hospitalization and Death in Nursing Home Elderly Residents With Coronary Artery Disease. *J Am Med Dir Assoc.* 2016; 17:1056-9.

33. Ingrasciotta Y, Sultana J, Giorgianni F, **Caputi AP**, Arcoraci V, Tari DU, Linguiti C, Perrotta M, Nucita A, Pellegrini F, Fontana A, Cavagna L, Santoro D, Trifirò G. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. *PLoS One.* 2014; 9: e89072.

34. Bettiol A, Lucenteforte E, Vannacci A, Lombardi N, Onder G, Agabiti N, Vitale C, Trifirò G, Corrao G, Roberto G, **Caputi AP**, Mugelli A, Chinellato A; Italian Group for Appropriate Drug prescription in the

Elderly (I-GrADE). Calcium Channel Blockers in Secondary Cardiovascular Prevention and Risk of Acute Events: Real-World Evidence from Nested Case-Control Studies on Italian Hypertensive Elderly. *Clin Drug Investig.* 2017; 37:1165-1174.

35. Ferrajolo C, Arcoraci V, Sullo MG, Rafaniello C, Sportiello L, Ferrara R, Cannata A, Pagliaro C, Tari MG, **Caputi AP**, Rossi F, Trifirò G, Capuano A. Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? *PLoS One.* 2014; 9:e102146.

36. Salvo F, Fourrier-Réglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, **Caputi AP**, Moore N, Sturkenboom MC, Pariente A; Investigators of Safety of Non-Steroidal Anti-Inflammatory Drugs: SOS Project. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. *Clin Pharmacol Ther.* 2011; 89:855-66.

37. Mannucci C, Navarra M, Pieratti A, Russo GA, **Caputi AP**, Calapai G. Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal. *Nicotine Tob Res* 2011; 13:239-47.

38. Oteri A, Trifirò G, Gagliostro MS, Tari DU, Moretti S, Bramanti P, Spina E, **Caputi AP**, Arcoraci V. Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. *Br J Clin Pharmacol* 2010; 70:514-22.

39. Bartolone S, Calzavara E, Russo GA, Carni A, Mannucci C, Pieratti A, **Caputi AP**, Calapai G. White cells count in smokers affected by rheumatic diseases. *Rheumatol Int.* 2012; 32:109-15.

40. Trifirò G, Gambassi G, Sen EF, **Caputi AP**, Bagnardi V, Brea J, Sturkenboom MC. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. *Ann Intern Med* 2010; 152:418-25,

41. Catania MA, Oteri A, Caiello P, Russo A, Salvo F, Giustini ES, **Caputi AP**, Polimeni G. Hemorrhagic cystitis induced by an herbal mixture. *South Med J*; 2010; 103:90-2.

42. Trifirò G, Sini G, Sturkenboom MC, Vanacore N, Mazzaglia G, **Caputi AP**, Cricelli C, Brignoli O, Aguglia E, Biggio G, Samani F. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia. *Int Clin Psychopharmacol* 2010; 25:22-8.

43. Calapai G, **Caputi AP**, Mannucci C, Gregg EO, Pieratti A, Aurora Russo G, Chaudhary N, Puntoni R, Lowe F, McEwan M, Bassi A, Morandi S, Nunziata A. A cross-sectional investigation of biomarkers of risk after a decade of smoking. *Inhal Toxicol* 2009; 21:1138-43.

44. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, **Caputi AP**, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. *Circulation.* 2009; 120:1598-605.

45. Trifirò G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salamé G, Catania MA, Salvo F, David A, Moore N, **Caputi AP**, Sturkenboom M, Molokhia M, Hippisley-Cox J, Acedo CD, van der Lei J, Fourrier-Reglat A; EU-ADR group. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? *Pharmacoepidemiol Drug Saf* 2009; 18:1176-84.

46. Polimeni G, Grugno R, Vitetta A, Cordici F, Alagna A, **Caputi AP**, Bramanti P. A case of topiramate-induced epistaxis. *Curr Drug Saf* 2009; 4:207-8.

47. Alacqua M, Trifirò G, Spina E, Moretti S, Tari DU, Bramanti P, **Caputi AP**, Arcoraci V. Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. *Epilepsy Res* 2009; 85:107-13.
48. Polimeni G, Russo A, Catania MA, Aiello A, Oteri A, Trifirò G, Calapai G, Sautebin L, Iacobelli M, **Caputi AP**. Drug safety information through the internet: the experience of an Italian website. *Drug Saf* 2009; 32:245-53.
49. Salvo F, De Sarro A, **Caputi AP**, Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. *Expert Opin Drug Saf* 2009; 8:111-8.
50. Oteri A, Catania MA, Russo A, Salvo F, Giacci L, **Caputi AP**, Polimeni G. Reversible acute hepatitis induced by rosuvastatin. *South Med J*. 2008; 101:768.
51. Calapai G, **Caputi AP**, Mannucci C, Russo GA, Gregg E, Puntoni R, Lowe F, McEwan M, Bassi A, Morandi S, Nunziata A. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. *Basic Clin Pharmacol Toxicol* 2009; 104:322-8.
52. Polimeni G, Grugno R, Cordici F, Vitetta A, **Caputi AP**, Bramanti P. Nocturnal enuresis after paroxetine abrupt discontinuation: a case report. *J Clin Psychopharmacol*. 2008; 28:589-91.
53. Corrao S, Arcoraci V, Arnone S, Calvo L, Scaglione R, Di Bernardo C, Lagalla R, **Caputi AP**, Licata G. Evidence-Based Knowledge Management: an approach to effectively promote good health-care decision-making in the Information Era. *Intern Emerg Med* 2009; 4:99-106.
54. Salvo F, Polimeni G, Cutroneo PM, Leone R, Confortic A, Moretti U, Motola D, Tuccori M, **Caputi AP**. Allergic reactions to oral drugs: A case/non-case study from an Italian spontaneous reporting database (GIF). *Pharmacol Res* 2008; 58:202-7.
55. Alacqua M, Trifirò G, Cavagna L, Caporali R, Montecucco CM, Moretti S, Tari DU, Galdo M, **Caputi AP**, Arcoraci V. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. *Arthritis Rheum*. 2008; 59:568-74.
56. Oteri A, Catania MA, Travaglini R, Russo A, Giustini SE, **Caputi AP**, Polimeni G. Gynecomastia possibly induced by rosuvastatin. *Pharmacotherapy*. 2008; 28:549-51.
57. Trifirò G, Savica R, Morgante L, Vanacore N, Tari M, Moretti S, Galdo M, Spina E, **Caputi AP**, Arcoraci V. Prescribing pattern of anti-Parkinson drugs in Southern Italy: Cross-sectional analysis in the years 2003-2005. *Parkinsonism Relat Disord*. 2008; 14:420-5.
58. Bitto A, Minutoli L, Altavilla D, Polito F, Fiumara T, Marini H, Galeano M, Calò M, Lo Cascio P, Bonaiuto M, Migliorato A, **Caputi AP**, Squadrito F. Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. *Pharmacol Res*. 2008; 57:159-69.
59. Calapai G, **Caputi AP**. Herbal medicines: can we do without pharmacist? *Evid Based Complement Alternat Med*. 2007; 4:41-3.
60. Trifirò G, Alacqua M, Corrao S, Moretti S, Tari DU, Galdo M; UVEC Group, **Caputi AP**, Arcoraci V. Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision. *Eur J Clin Pharmacol*. 2008; 64:619-25.
61. Genazzani AA, Biggio G, **Caputi AP**, Del Tacca M, Drago F, Fantozzi R, Canonico PL. Biosimilar drugs : concerns and opportunities. *BioDrugs*. 2007; 21:351-6.



62. Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, **Caputi AP**, Musolino R, Spina E, Trifirò G. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population- based study in the years 2000-2005. *Eur J Neurol.* 2007; 14: 1317-21.
63. Mannucci C, Pieratti A, Firenzuoli F, **Caputi AP**, Calapai G. Serotonin mediates beneficial effects of *Hypericum perforatum* on nicotine withdrawal signs. *Phytomedicine.* 2007; 14:645-51.
64. Oteri A, Salvo F, **Caputi AP**, Calapai G. Intake of energy drinks in association with alcoholic beverages in a cohort of students of the School of Medicine of the University of Messina. *Alcohol Clin Exp Res.* 2007; 31:1677-80.
65. Polimeni G, Cutroneo P, Gallo A, Gallo S, Spina E, **Caputi AP**. Rabeprazole and psychiatric symptoms. *Ann Pharmacother.* 2007; 41:1315-7.
66. Cutroneo P, Polimeni G, Curcuruto R, Calapai G, **Caputi AP**. Adverse reactions to contrast media: an analysis from spontaneous reporting data. *Pharmacol Res.* 2007; 56:35-41.
67. Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O, Motola D, Dusi G, **Caputi AP**. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. *J Antimicrob Chemother.* 2007; 60:121-6.
68. Galatti L, Mazzaglia G, Greco A, Sessa E, Cricelli C, Schito GC, Nicoletti G, Spina E, **Caputi AP**. Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. *Pharmacoepidemiol Drug Saf.* 2007; 16:422-8.
69. Failla M, Genovese T, Mazzon E, Gili E, Muia C, Sortino M, Crimi N, **Caputi AP**, Cuzzocrea S, Vancheri C. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. *Respir Res.* 2006; 21:7:137.
70. Trifiro G, Verhamme KM, Ziere G, **Caputi AP**, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. *Pharmacoepidemiol Drug Saf.* 2007; 16:538-44.
71. Trifiro G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, **Caputi AP**, Arcoraci V; UVEC group. Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. *Pharmacoepidemiol Drug Saf.* 2007; 16:552-9.
72. Trifiro G, Corrao S, Alacqua M, Moretti S, Tari M, **Caputi AP**, Arcoraci V; UVEC Group. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. *Br J Clin Pharmacol.* 2006; 62:582-90.
73. Bellomo M, Marini H, Adamo EB, Catania MA, Mannucci C, Squadrito F, Marini R, Giuffrida R, Grasso G, Buemi M, **Caputi AP**, Giacca M, Calapai G. Vascular endothelial growth factor induces brain erythropoietin expression? *Funct Neurol.* 2006; 21:87-91.
74. Cuzzocrea S, Nocentini G, Di Paola R, Agostini M, Mazzon E, Ronchetti S, Crisafulli C, Esposito E, **Caputi AP**, Riccardi C. Proinflammatory role of glucocorticoid-induced TNF receptor-related gene in acute lung inflammation. *J Immunol.* 2006; 177:631-41.
75. Mannucci C, Tedesco M, Bellomo M, **Caputi AP**, Calapai G. Long-term effects of nicotine on the forced swimming test in mice: an experimental model for the study of depression caused by smoke. *Neurochem Int.* 2006; 49:481-6.

76. Mazzon E, Sautebin L, **Caputi AP**, Cuzzocrea S. 5-lipoxygenase modulates the alteration of paracellular barrier function in mice ileum during experimental colitis. *Shock*. 2006; 25:377-83.
77. Cuzzocrea S, Mazzon E, Di Paola R, Muia C, Crisafulli C, Dugo L, Collin M, Britti D, **Caputi AP**, Thiernemann C. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. *Clin Immunol*. 2006; 120:57-67.
78. Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Muia C, Crisafulli C, **Caputi AP**. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. *J Leukoc Biol*. 2006; 79:999-1010.
79. Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muia C, Crisafulli C, **Caputi AP**, Thiernemann C. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. *Crit Care Med*. 2006; 34:1168-77.
80. Galatti L, Sessa A, Mazzaglia G, Pecchioli S, Rossi A, Cricelli C, Schito GC, Nicoletti G, **Caputi AP**. Antibiotic prescribing for acute and recurrent cystitis in primary care: a 4 years descriptive study. *J Antimicrob Chemother*. 2006; 57:551-6.
81. Muia C, Mazzon E, Crisafulli C, Di Paola R, Genovese T, **Caputi AP**, Cuzzocrea S. ROLE of endogenous peroxisome proliferator-activated receptor-alpha(PPAR-alpha) ligands in the development of gut ischemia and reperfusion in mice. *Shock*. 2006; 25:17-22.
82. Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Muia C, **Caputi AP**, Salvemini D. Synergistic interaction between methotrexate and a superoxide dismutase mimetic: pharmacologic and potential clinical significance. *Arthritis Rheum*. 2005; 52:3755-60.
83. Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, **Caputi AP**, Cuzzocrea S. Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha in the development of bleomycin-induced lung injury. *Shock*. 2005; 24:547-55.
84. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, Cricelli C, Brignoli O, **Caputi AP**. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. *J Hypertens*. 2005; 23:2093-100.
85. Di Paola R, Muia C, Mazzon E, Genovese T, Crisafulli C, Menegazzi M, **Caputi AP**, Suzuki H, Cuzzocrea S. Effects of *Hypericum perforatum* extract in a rat model of ischemia and reperfusion injury. *Shock*. 2005; 24:255-63.
86. Genovese T, Di Paola R, Mazzon E, Muia C, **Caputi AP**, Cuzzocrea S. Melatonin limits lung injury in bleomycin treated mice. *J Pineal Res*. 2005; 39:105-12.
87. Cuzzocrea S, Ayroldi E, Di Paola R, Agostini M, Mazzon E, Bruscoli S, Genovese T, Ronchetti S, **Caputi AP**, Riccardi C. Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis. *FASEB J*. 2005; 19:1253-65.
88. Muia C, Mazzon E, Di Paola R, Genovese T, Menegazzi M, **Caputi AP**, Suzuki H, Cuzzocrea S. Green tea polyphenol extract attenuates ischemia/reperfusion injury of the gut. *Naunyn Schmiedebergs Arch Pharmacol*. 2005; 371:364-74.
89. Mannucci C, Catania MA, Adamo EB, Bellomo M, **Caputi AP**, Calapai G. Long-term effects of high doses of nicotine on feeding behavior and brain nitric oxide synthase activity in female mice. *J Pharmacol Sci*. 2005;98:232-8.

90. Genovese T, Cuzzocrea S, Di Paola R, Failla M, Mazzon E, Sortino MA, Frasca G, Gili E, Crimi N, **Caputi AP**, Vancheri C. Inhibition or knock out of inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. *Respir Res.* 2005; 6:58.
91. Cuzzocrea S, Mazzon E, Paola RD, Genovese T, Muia C, **Caputi AP**, Salvemini D. Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. *Arthritis Rheum.* 2005; 52(6):1929-40.
92. Cuzzocrea S, Rossi A, Mazzon E, Di Paola R, Genovese T, Muia C, **Caputi AP**, Sautebin L. 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. *Lab Invest.* 2005; 85: 808-22.
93. Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Patel NS, Britti D, de Majo M, **Caputi AP**, Thiemermann C. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. *Arthritis Rheum.* 2005; 52:940-50.
94. Genovese T, Cuzzocrea S, Di Paola R, Mazzon E, Mastruzzo C, Catalano P, Sortino M, Crimi N, **Caputi AP**, Thiemermann C, Vancheri C. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. *Eur Respir J.* 2005; 25:225-34.
95. Trifiro G, Calogero G, Ippolito FM, Cosentino M, Giuliani R, Conforti A, Venegoni M, Mazzaglia G, **Caputi AP**. Adverse drug events in emergency department population: a prospective Italian study. *Pharmacoepidemiol Drug Saf.* 2005;14:333-40.
96. Trifiro G, Spina E, Brignoli O, Sessa E, **Caputi AP**, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. *Eur J Clin Pharmacol.* 2005; 61:47-53.
97. Galatti L, Giustini SE, Sessa A, Polimeni G, Salvo F, Spina E, **Caputi AP**. Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy. *Pharmacol Res.* 2005; 51:211-6.
98. Genovese T, Mazzon E, Di Paola R, Muia C, Threadgill MD, **Caputi AP**, Thiemermann C, Cuzzocrea S. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and the development of bleomycin-induced lung injury. *J Pharmacol Exp Ther.* 2005; 313:529-38.
99. Altavilla D, Marini H, Seminara P, Squadrito G, Minutoli L, Passaniti M, Bitto A, Calapai G, Calo M, **Caputi AP**, Squadrito F. Protective effects of antioxidant raxofelast in alcohol-induced liver disease in mice. *Pharmacology.* 2005; 74:6-14.
100. Filippi A, Sessa E, Trifiro G, Mazzaglia G, Pecchioli S, **Caputi AP**, Cricelli C. Oral anticoagulant therapy in Italy: prescribing prevalence and clinical reasons. *Pharmacol Res.* 2004; 50:601-3.
101. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, **Caputi AP**, Thiemermann C. Tempol reduces the activation of nuclear factor-kappaB in acute inflammation. *Free Radic Res.* 2004;38:813-9.
102. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Centorrino T, **Caputi AP**. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. *Lab Invest.* 2004; 84:1643-54.

103. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, **Caputi AP**. WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. *Shock*. 2004; 22:340-6.
104. Sautebin L, Rossi A, Serraino I, Dugo P, Di Paola R, Mondello L, Genovese T, Britti D, Peli A, Dugo G, **Caputi AP**, Cuzzocrea S. Effect of anthocyanins contained in a blackberry extract on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. *Planta Med*. 2004; 70:745-52.
105. Cuzzocrea S, Nocentini G, Di Paola R, Mazzon E, Ronchetti S, Genovese T, Muia C, **Caputi AP**, Riccardi C. Glucocorticoid-induced TNF receptor family gene (GITR) knockout mice exhibit a resistance to splanchnic artery occlusion (SAO) shock. *J Leukoc Biol*. 2004; 76:933-40.
106. Guarini S, Cainazzo MM, Giuliani D, Mioni C, Altavilla D, Marini H, Bigiani A, Ghiaroni V, Passaniti M, Leone S, Bazzani C, **Caputi AP**, Squadrito F, Bertolini A. Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. *Cardiovasc Res*. 2004; 63:357-65.
107. Cuzzocrea S, Rossi A, Serraino I, Di Paola R, Dugo L, Genovese T, Britti D, Sciarra G, De Sarro A, **Caputi AP**, Sautebin L. Role of 5-lipoxygenase in the multiple organ failure induced by zymosan. *Intensive Care Med*. 2004; 30:1935-43.
108. Genovese T, Di Paola R, Catalano P, Li JH, Xu W, Massuda E, **Caputi AP**, Zhang J, Cuzzocrea S. Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice. *Crit Care Med*. 2004; 32:1365-74.
109. Di Paola R, Genovese T, **Caputi AP**, Threadgill M, Thiemermann C, Cuzzocrea S. Beneficial effects of 5-aminoisoquinolinone, a novel, potent, water-soluble, inhibitor of poly (ADP-ribose) polymerase, in a rat model of splanchnic artery occlusion and reperfusion. *Eur J Pharmacol*. 2004; 492:203-10.
110. Scordo MG, **Caputi AP**, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. *Pharmacol Res*. 2004; 50:195-200.
111. Fries W, Mazzon E, Sturiale S, Giofre MR, Lo Presti MA, Cuzzocrea S, Campo GM, **Caputi AP**, Longo G, Sturniolo GC. A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat. *Life Sci*. 2004; 74:2749-56.
112. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Britti D, Patel NS, Di Paola R, Genovese T, Di Rosa M, **Caputi AP**, Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. *Intensive Care Med*. 2004; 30:951-6.
113. Imperatore F, Cuzzocrea S, Luongo C, Liguori G, Scafuro A, De Angelis A, Rossi F, **Caputi AP**, Filippelli A. Hyperbaric oxygen therapy prevents vascular derangement during zymosan-induced multiple-organ-failure syndrome. *Intensive Care Med*. 2004;30:1175-81.
114. Dugo L, Marzocco S, Mazzon E, Di Paola R, Genovese T, **Caputi AP**, Cuzzocrea S. Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation. *Br J Pharmacol*. 2004; 141:979-87.
115. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Fulia F, Cuzzocrea E, Di Rosa M, **Caputi AP**, Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. *Crit Care Med*. 2004; 32:457-66.

116. Cuzzocrea S, Mazzone E, Dugo L, Di Paola R, **Caputi AP**, Salvemini D. Superoxide: a key player in hypertension. *FASEB J*. 2004; 18:94-101.
117. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, **Caputi AP**, Thiernemann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. *Eur J Pharmacol*. 2004; 483:79-93.
118. Cuzzocrea S, Mazzone E, Di Paola R, Genovese T, Serraino I, Dugo L, Cuzzocrea E, Fulia F, **Caputi AP**, Salvemini D. Protective effects of M40401, a selective superoxide dismutase mimetic, on zymosan-induced nonseptic shock. *Crit Care Med*. 2004; 32:157-67.
119. Marzocco S, Di Paola R, Autore G, Mazzone E, Pinto A, **Caputi AP**, Thiernemann C, Cuzzocrea S. Calpain inhibitor I reduces intestinal ischemia-reperfusion injury in the rat. *Shock*. 2004; 21:38-44.
120. Cuzzocrea S, Mazzone E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, **Caputi AP**, Thiernemann C. Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. *Arthritis Rheum*. 2003; 48:3544-56.
121. Cricelli C, Mazzaglia G, Samani F, Marchi M, Sabatini A, Nardi R, Ventriglia G, **Caputi AP**. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. *J Public Health Med*. 2003; 25:254-7.
122. Rossi A, Serraino I, Dugo P, Di Paola R, Mondello L, Genovese T, Morabito D, Dugo G, Sautebin L, **Caputi AP**, Cuzzocrea S. Protective effects of anthocyanins from blackberry in a rat model of acute lung inflammation. *Free Radic Res*. 2003; 37:891-900.
123. Mazzaglia G, **Caputi AP**, Rossi A, Bettoncelli G, Stefanini G, Ventriglia G, Nardi R, Brignoli O, Cricelli C. Exploring patient- and doctor-related variables associated with antibiotic prescribing for respiratory infections in primary care. *Eur J Clin Pharmacol*. 2003; 59:651-7.
124. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, **Caputi AP**, Thiernemann C. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. *Br J Pharmacol*. 2003; 140:366-76.
125. Cuzzocrea S, Rossi A, Serraino I, Di Paola R, Dugo L, Genovese T, Britti D, Sciarra G, De Sarro A, **Caputi AP**, Sautebin L. 5-lipoxygenase knockout mice exhibit a resistance to acute pancreatitis induced by cerulein. *Immunology*. 2003; 110:120-30.
126. Cuzzocrea S, Rossi A, Serraino I, Di Paola R, Dugo L, Genovese T, **Caputi AP**, Sautebin L. 5-lipoxygenase knockout mice exhibit a resistance to splanchnic artery occlusion shock. *Shock*. 2003; 20:230-6.
127. Cuzzocrea S, Rossi A, Pisano B, Di Paola R, Genovese T, Patel NS, Cuzzocrea E, Ianaro A, Sautebin L, Fulia F, Chatterjee PK, **Caputi AP**, Thiernemann C. Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. *Intensive Care Med*. 2003; 29:2016-25.
128. Bellomo M, Adamo EB, Deodato B, Catania MA, Mannucci C, Marini H, Marciano MC, Marini R, Sapienza S, Giacca M, **Caputi AP**, Squadrito F, Calapai G. Enhancement of expression of vascular endothelial growth factor after adeno-associated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil. *Pharmacol Res*. 2003; 48:309-17.

129. Serraino I, Dugo L, Dugo P, Mondello L, Mazzon E, Dugo G, **Caputi AP**, Cuzzocrea S. Protective effects of cyanidin-3-O-glucoside from blackberry extract against peroxynitrite-induced endothelial dysfunction and vascular failure. *Life Sci.* 2003; 73:1097-114.
130. Cuzzocrea S, Rossi A, Serraino I, Mazzon E, Di Paola R, Dugo L, Genovese T, Calabro B, **Caputi AP**, Sautebin L. 5-Lipoxygenase knockout mice exhibit a resistance to pleurisy and lung injury caused by carrageenan. *J Leukoc Biol.* 2003 ;73:739-46.
131. Catania MA, Firenzuoli F, Crupi A, Mannucci C, **Caputi AP**, Calapai G. *Hypericum perforatum* attenuates nicotine withdrawal signs in mice. *Psychopharmacology (Berl).* 2003; 169:186-9.
132. Bucolo C, Cuzzocrea S, Mazzon E, **Caputi AP**. Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. *Invest Ophthalmol Vis Sci.* 2003; 44:1178-84.
133. Cuzzocrea S, Ianaro A, Wayman NS, Mazzon E, Pisano B, Dugo L, Serraino I, Di Paola R, Chatterjee PK, Di Rosa M, **Caputi AP**, Thiemermann C. The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. *Br J Pharmacol.* 2003; 138:678-88.
134. Cuzzocrea S, Mazzon E, Dugo L, Genovese T, Di Paola R, Ruggeri Z, Vegeto E, **Caputi AP**, Van De Loo FA, Puzzolo D, Maggi A. Inducible nitric oxide synthase mediates bone loss in ovariectomized mice. *Endocrinology.* 2003; 144:1098-107.
135. Squadrito F, Deodato B, Bova A, Marini H, Saporito F, Calo M, Giacca M, Minutoli L, Venuti FS, **Caputi AP**, Altavilla D. Crucial role of nuclear factor-kappaB in neointimal hyperplasia of the mouse carotid artery after interruption of blood flow. *Atherosclerosis.*2003; 166:233-42.
136. Rossi A, Cuzzocrea S, Mazzon E, Serraino I, De Sarro A, Dugo L, Felice MR, Van de Loo FA, Di Rosa M, Musci G, **Caputi AP**, Sautebin L. Regulation of prostaglandin generation in carrageenan-induced pleurisy by inducible nitric oxide synthase in knockout mice. *Life Sci.* 2003; 72:1199-208.
137. Catania MA, Crupi A, Firenzuoli F, Parisi A, Sturiale A, Squadrito F, **Caputi AP**, Calapai G. Oral administration of a soy extract improves endothelial dysfunction in ovariectomized rats. *Planta Med.*2002; 68:1142-4.
138. Mazzon E, De Sarro A, **Caputi AP**, Cuzzocrea S. Role of tight junction derangement in the endothelial dysfunction elicited by exogenous and endogenous peroxynitrite and poly(ADP-ribose) synthetase. *Shock.* 2002; 18:434-9.
139. Cuzzocrea S, Chatterjee PK, Mazzon E, Serraino I, Dugo L, Centorrino T, Barbera A, Ciccolo A, Fulia F, McDonald MC, **Caputi AP**, Thiemermann C. Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat. *Crit Care Med.* 2002; 30:2284-94.
140. Mazzon E, Puzzolo D, **Caputi AP**, Cuzzocrea S. Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. *Mol Med.* 2002 ;8:353-66.
141. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, Di Paola R, Serraino I, Britti D, **Caputi AP**, Thiemermann C. Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. *Eur J Pharmacol.* 2002; 453:119-29.
142. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, Genovese T, De Sarro A, **Caputi AP**. Absence of endogenous interleukin-10 enhances the evolution of acute lung injury. *Eur Cytokine Netw.* 2002; 13:285-97.

143. Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, De Sarro A, Van de Loo FA, **Caputi AP**, Thiernemann C. Role of induced nitric oxide in the initiation of the inflammatory response after posts ischemic injury. *Shock*. 2002; 18:169-76.
144. Cuzzocrea S, Mazzon E, Dugo L, Centorrino T, Ciccolo A, McDonald MC, de Sarro A, **Caputi AP**, Thiernemann C. Absence of endogenous interleukin-6 enhances the inflammatory response during acute pancreatitis induced by cerulein in mice. *Cytokine*. 2002; 18:274-85.
145. Ottana R, Mazzon E, Dugo L, Monforte F, Maccari R, Sautebin L, De Luca G, Vigorita MG, Alcaro S, Ortuso F, **Caputi AP**, Cuzzocrea S. Modeling and biological evaluation of 3,3'-bis[2-(4-methoxyphenyl)-thiazolidin-4-one], a new synthetic cyclooxygenase-2 inhibitor. *Eur J Pharmacol*. 2002; 448:71-80.
146. Mazzon E, Dugo L, Li JH, Di Paola R, Genovese T, **Caputi AP**, Zhang J, Cuzzocrea S. GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. *Biochem Pharmacol*. 2002; 64:327-37.
147. Cucinotta G, Mazzaglia G, Toscano MA, Arcoraci V, Tempera G, Salmeri M, Rosignoli M, Bottaro G, Boccazzi A, Nicoletti G, **Caputi AP**. Exploring the variability in antibiotic prescribing profiles among paediatricians from two different areas of Italy. *Pharmacol Res*. 2002; 45:369-74.
148. Dugo L, Chatterjee PK, Mazzon E, McDonald MC, Paola RD, Fulia F, **Caputi AP**, Thiernemann C, Cuzzocrea S. The tyrosine kinase inhibitor tyrphostin AG 126 reduces the multiple organ failure induced by zymosan in the rat. *Intensive Care Med*. 2002; 28:775-88.
149. Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, Ruggeri P, Campo GM, Calapai G, **Caputi AP**, Squadrito G. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. *Atherosclerosis*. 2002; 163:339-47.
150. Altavilla D, Squadrito G, Minutoli L, Deodato B, Bova A, Sardella A, Seminara P, Passaniti M, Urna G, Venuti SF, **Caputi AP**, Squadrito F. Inhibition of nuclear factor-kappaB activation by IRFI 042, protects against endotoxin-induced shock. *Cardiovasc Res*. 2002; 54:684-93.
151. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Centorrino T, Ciccolo A, Van de Loo FA, Britti D, **Caputi AP**, Thiernemann C. Inducible nitric oxide synthase-deficient mice exhibit resistance to the acute pancreatitis induced by cerulein. *Shock*. 2002; 17:416-22.
152. Cuzzocrea S, Mazzon E, Sautebin L, Dugo L, Serraino I, De Sarro A, **Caputi AP**. Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. *Biochem Pharmacol*. 2002;63:785-95.
153. Cuzzocrea S, Wayman NS, Mazzon E, Dugo L, Di Paola R, Serraino I, Britti D, Chatterjee PK, **Caputi AP**, Thiernemann C. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. *Mol Pharmacol*. 2002; 61:997-1007.
154. Mazzon E, Dugo L, De SA, Li JH, **Caputi AP**, Zhang J, Cuzzocrea S. Beneficial effects of GPI 6150, an inhibitor of poly(ADP-ribose) polymerase in a rat model of splanchnic artery occlusion and reperfusion. *Shock*. 2002; 17:222-7.

155. Mazzaglia G, Arcoraci V, Blandino G, Miragliotta G, Schito AM, Pasquantonio G, Nicoletti G, **Caputi AP**. Antibiotic prescribing for dental conditions: a community-based study in southern Italy. *J Chemother*. 2002; 14:65-70.
156. Catania MA, Marciano MC, Parisi A, Sturiale A, Buemi M, Grasso G, Squadrito F, **Caputi AP**, Calapai G. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. *Eur J Pharmacol*. 2002; 437:147-50.
157. Cuzzocrea S, McDonald MC, Mazzon E, Dugo L, Serraino I, Threadgill M, **Caputi AP**, Thiemermann C. Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase, in a rodent model of lung injury. *Biochem Pharmacol*. 2002; 63:293-304.
158. Cuzzocrea S, Chatterjee PK, Mazzon E, Dugo L, Serraino I, Britti D, Mazzullo G, **Caputi AP**, Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. *Br J Pharmacol*. 2002; 135:496-510.
159. Altavilla D, Saitta A, Squadrito G, Galeano M, Venuti SF, Guarini S, Bazzani C, Bertolini A, **Caputi AP**, Squadrito F. Evidence for a role of nuclear factor-kappaB in acute hypovolemic hemorrhagic shock. *Surgery*. 2002; 131:50-8.
160. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Britti D, De Maio M, **Caputi AP**. Absence of endogenous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. *Eur Cytokine Netw*. 2001; 12:568-80.
161. Salvemini D, Mazzon E, Dugo L, Serraino I, De Sarro A, **Caputi AP**, Cuzzocrea S. Amelioration of joint disease in a rat model of collagen-induced arthritis by M40403, a superoxide dismutase mimetic. *Arthritis Rheum*. 2001; 44:2909-21.
162. Cuzzocrea S, Mazzon E, Dugo L, **Caputi AP**, Riley DP, Salvemini D. Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. *Eur J Pharmacol*. 2001; 432:79-89.
163. Cuzzocrea S, Mazzon E, Serraino I, Dugo L, Centorrino T, Ciccolo A, Sautebin L, **Caputi AP**. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. *Eur J Pharmacol*. 2001; 431:91-102.
164. Cuzzocrea S, Mazzon E, Sautebin L, Serraino I, Dugo L, Calabro G, **Caputi AP**, Maggi A. The protective role of endogenous estrogens in carrageenan-induced lung injury in the rat. *Mol Med*. 2001; 7:478-87.
165. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Ciliberto G, Parisi A, De Sarro G, **Caputi AP**. Interleukin-6 involvement in antidepressant action of *Hypericum perforatum*. *Pharmacopsychiatry*. 2001; 34:S8-10.
166. Dugo L, Serraino I, Fulia F, De Sarro A, **Caputi AP**, Cuzzocrea S. Effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in an acute model of inflammation. *J Pineal Res*. 2001; 31:76-84.
167. Mazzon E, Britti D, De Sarro A, **Caputi AP**, Cuzzocrea S. Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. *Eur J Pharmacol*. 2001; 424:75-83.
168. Cuzzocrea S, Mazzon E, Dugo L, Barbera A, Centorrino T, Ciccolo A, Fonti MT, **Caputi AP**. Inducible nitric oxide synthase knockout mice exhibit resistance to the multiple organ failure induced by zymosan. *Shock*. 2001; 16:51-8.



169. Altavilla D, Saitta A, Guarini S, Galeano M, Squadrito G, Cucinotta D, Santamaria LB, Mazzeo AT, Campo GM, Ferlito M, Minutoli L, Bazzani C, Bertolini A, **Caputi AP**, Squadrito F. Oxidative stress causes nuclear factor-kappaB activation in acute hypovolemic hemorrhagic shock. *Free Radic Biol Med.* 2001; 30:1055-66.
170. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Ciccolo A, Centorrino T, De Sarro A, **Caputi AP**. Protective effects of n-acetylcysteine on lung injury and red blood cell modification induced by carrageenan in the rat. *FASEB J.* 2001; 15:1187-200.
171. Cuzzocrea S, McDonald MC, Mazzon E, Mota-Filipe H, Centorrino T, Terranova ML, Ciccolo A, Britti D, **Caputi AP**, Thiemermann C. Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. *Gut.* 2001; 48:478-88.
172. Mazzon E, Serraino I, Li JH, Dugo L, **Caputi AP**, Zhang J, Cuzzocrea S. GPI 6150, a poly (ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation. *Eur J Pharmacol.* 2001; 415:85-94.
173. Altavilla D, Saitta A, Galeano M, Squadrito G, Marino D, Minutoli L, Calapai G, Deodato B, D'Anna R, Corrado F, **Caputi AP**, Squadrito F. The phytoestrogen alpha-zearalenol reverses endothelial dysfunction induced by oophorectomy in rats. *Lab Invest.* 2001; 81:125-32.
174. Salvemini D, Mazzon E, Dugo L, Riley DP, Serraino I, **Caputi AP**, Cuzzocrea S. Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic, M40403. *Br J Pharmacol.* 2001; 132:815-27.
175. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Centorrino T, Lepore V, Terranova ML, Ciccolo A, **Caputi AP**, Thiemermann C. Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. *Crit Care Med.* 2001; 29:102-11.
176. Cuzzocrea S, Riley DP, **Caputi AP**, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. *Pharmacol Rev.* 2001; 53:135-59.
177. Cuzzocrea S, Mazzon E, Serraino I, Lepore V, Terranova ML, Ciccolo A, **Caputi AP**. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. *J Pineal Res.* 2001; 30:1-12.
178. Cuzzocrea S, Mazzon E, Dugo L, **Caputi AP**, Aston K, Riley DP, Salvemini D. Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion. *Br J Pharmacol.* 2001; 132:19-29.
179. Cuzzocrea S, McDonald MC, Mazzon E, Siriwardena D, Serraino I, Dugo L, Britti D, Mazzullo G, **Caputi AP**, Thiemermann C. Calpain inhibitor I reduces the development of acute and chronic inflammation. *Am J Pathol.* 2000; 157:2065-79.
180. Calapai G, Crupi A, Firenzuoli F, Marciano MC, Squadrito F, Inferrera G, Parisi A, Rizzo A, Crisafulli C, Fiore A, **Caputi AP**. Neuroprotective effects of Ginkgo biloba extract in brain ischemia are mediated by inhibition of nitric oxide synthesis. *Life Sci.* 2000; 67:2673-83.
181. Altavilla D, Squadrito F, Campo GM, Saitta A, Squadrito G, Quartarone C, Deodato B, Arlotta M, Ferlito M, Minutoli L, Tringali M, Urna G, Sardella A, **Caputi AP**. The reduction of myocardial damage and leukocyte polymorphonuclear accumulation following coronary artery occlusion by the tyrosine kinase inhibitor tyrphostin AG 556. *Life Sci.* 2000; 67:2615-29.

182. Cuzzocrea S, Mazzon E, Bevilacqua C, Costantino G, Britti D, Mazzullo G, De Sarro A, **Caputi AP**. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. *Br J Pharmacol*. 2000; 131:1399-407.
183. Cuzzocrea S, Mazzon E, De Sarro A, **Caputi AP**. Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability. *Mol Med*. 2000; 6:766-78.
184. Cuzzocrea S, Mazzon E, Calabro G, Dugo L, De Sarro A, van De LOO FA, **Caputi AP**. Inducible nitric oxide synthase-knockout mice exhibit resistance to pleurisy and lung injury caused by carrageenan. *Am J Respir Crit Care Med*. 2000; 162:1859-66.
185. Cuzzocrea S, Costantino G, Gitto E, Mazzon E, Fulia F, Serraino I, Cordaro S, Barberi I, De Sarro A, **Caputi AP**. Protective effects of melatonin in ischemic brain injury. *J Pineal Res*. 2000; 29:217-27.
186. Cuzzocrea S, McDonald MC, Mazzon E, Dugo L, Lepore V, Fonti MT, Ciccolo A, Terranova ML, **Caputi AP**, Thiernemann C. Tempol, a membrane-permeable radical scavenger, reduces dinitrobenzene sulfonic acid-induced colitis. *Eur J Pharmacol*. 2000; 406:127-37.
187. Cuzzocrea S, McDonald MC, Mazzon E, Mota-Filipe H, Lepore V, Ciccolo A, Terranova ML, Britti D, **Caputi AP**, Thiernemann C. The tyrosine kinase inhibitor tyrphostin AG 126 reduced the development of colitis in the rat. *Lab Invest*. 2000; 80:1439-53.
188. Cuzzocrea S, McDonald MC, Mazzon E, Siriwardena D, Costantino G, Fulia F, Cucinotta G, Gitto E, Cordaro S, Barberi I, De Sarro A, **Caputi AP**, Thiernemann C. Effects of tempol, a membrane-permeable radical scavenger, in a gerbil model of brain injury. *Brain Res*. 2000; 875:96-106.
189. Cuzzocrea S, Mazzon E, Costantino G, Serraino I, De Sarro A, **Caputi AP**. Effects of n-acetylcysteine in a rat model of ischemia and reperfusion injury. *Cardiovasc Res*. 2000; 47:537-48.
190. Altavilla D, Deodato B, Campo GM, Arlotta M, Miano M, Squadrito G, Saitta A, Cucinotta D, Ceccarelli S, Ferlito M, Tringali M, Minutoli L, **Caputi AP**, Squadrito F. IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappaB and reduces the inflammatory response in myocardial ischemia-reperfusion injury. *Cardiovasc Res*. 2000; 47:515-28.
191. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Costantino G, **Caputi AP**, Thiernemann C. Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of splanchnic artery occlusion and reperfusion. *Shock*. 2000; 14:150-6.
192. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, **Caputi AP**, Buemi M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. *Eur J Pharmacol*. 2000; 401:349-56.
193. Cuzzocrea S, Mazzon E, Costantino G, Serraino I, Dugo L, Calabro G, Cucinotta G, De Sarro A, **Caputi AP**. Beneficial effects of n-acetylcysteine on ischaemic brain injury. *Br J Pharmacol*. 2000; 130:1219-26.
194. Cuzzocrea S, McDonald MC, Mazzon E, Siriwardena D, Calabro G, Britti D, Mazzullo G, De Sarro A, **Caputi AP**, Thiernemann C. The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation. *Am J Pathol*. 2000; 157:145-58.
195. Cuzzocrea S, Misko TP, Costantino G, Mazzon E, Micali A, **Caputi AP**, Macarthur H, Salvemini D. Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion. *FASEB J*. 2000; 14:1061-72.

196. Squadrito F, Altavilla D, Squadrito G, Ferlito M, Deodato B, Arlotta M, Minutoli L, Campo GM, Bova A, Quartarone C, Urna G, Sardella A, Saitta A, **Caputi AP**. Protective effects of cyclosporin-A in splanchnic artery occlusion shock. *Br J Pharmacol*. 2000; 130:339-44.
197. Cuzzocrea S, Santagati S, Sautebin L, Mazzon E, Calabro G, Serraino I, **Caputi AP**, Maggi A. 17beta-estradiol antiinflammatory activity in carrageenan-induced pleurisy. *Endocrinology*. 2000; 141:1455-63.
198. Squadrito F, Altavilla D, Squadrito G, Saitta A, Deodato B, Arlotta M, Minutoli L, Quartarone C, Ferlito M, **Caputi AP**. Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia- reperfusion injury. *J Mol Cell Cardiol*. 2000; 32:429-40.
199. Squadrito F, Altavilla D, Squadrito G, Saitta A, Cucinotta D, Minutoli L, Deodato B, Ferlito M, Campo GM, Bova A, **Caputi AP**. Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. *Cardiovasc Res*. 2000; 45:454-62.
200. Cuzzocrea S, Imperatore F, Costantino G, Luongo C, Mazzon E, Scafuro MA, Mangoni G, **Caputi AP**, Rossi F, Filippelli A. Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat. *Shock*. 2000; 13:197-203.
201. Cuzzocrea S, McDonald MC, Filipe HM, Costantino G, Mazzon E, Santagati S, **Caputi AP**, Thiernemann C. Effects of tempol, a membrane-permeable radical scavenger, in a rodent model of carrageenan-induced pleurisy. *Eur J Pharmacol*. 2000; 390:209-22.
202. Cuzzocrea S, McDonald MC, Mota-Filipe H, Mazzon E, Costantino G, Britti D, Mazzullo G, **Caputi AP**, Thiernemann C. Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of collagen-induced arthritis. *Arthritis Rheum*. 2000; 43:320-8.
203. Cuzzocrea S, Costantino G, Mazzon E, Micali A, De Sarro A, **Caputi AP**. Beneficial effects of melatonin in a rat model of splanchnic artery occlusion and reperfusion. *J Pineal Res*. 2000; 28:52-63.
204. Squadrito F, Bagnato G, Altavilla D, Ferlito M, Campo GM, Squadrito G, Urna G, Sardella A, Arlotta M, Minutoli L, Quartarone C, Saitta A, **Caputi AP**. Effect of sulfatide on acute lung injury during endotoxemia in rats. *Life Sci*. 1999; 65:2541-52.
205. Deodato B, Altavilla D, Squadrito G, Campo GM, Arlotta M, Minutoli L, Saitta A, Cucinotta D, Calapai G, **Caputi AP**, Miano M, Squadrito F. Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury. *Br J Pharmacol*. 1999; 128:1683-90.
206. Cuzzocrea S, Costantino G, Mazzon E, De Sarro A, **Caputi AP**. Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in zymosan-induced shock. *Br J Pharmacol*. 1999; 128:1241-51.
207. El-Sokkary GH, Reiter RJ, Cuzzocrea S, **Caputi AP**, Hassanein AF, Tan DX. Role of melatonin in reduction of lipid peroxidation and peroxynitrite formation in non-septic shock induced by zymosan. *Shock*. 1999; 12:402-8.
208. Cuzzocrea S, Tan DX, Costantino G, Mazzon E, **Caputi AP**, Reiter RJ. The protective role of endogenous melatonin in carrageenan-induced pleurisy in the rat. *FASEB J*. 1999; 13:1930-8.
209. Cuzzocrea S, Sautebin L, De Sarro G, Costantino G, Rombola L, Mazzon E, Ialenti A, De Sarro A, Ciliberto G, Di Rosa M, **Caputi AP**, Thiernemann C. Role of IL-6 in the pleurisy and lung injury caused by carrageenan. *J Immunol*. 1999; 163:5094-104.

210. Squadrito F, Guarini S, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Cucinotta D, Bazzani C, Cainazzo MM, Mioni C, Bertolini A, **Caputi AP**. Adrenocorticotropin reverses vascular dysfunction and protects against splanchnic artery occlusion shock. *Br J Pharmacol*. 1999; 128:816-22.
211. Calapai G, Corica F, Corsonello A, Sautebin L, Di Rosa M, Campo GM, Buemi M, Mauro VN, **Caputi AP**. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. *J Clin Invest*. 1999; 104:975-82.
212. Cuzzocrea S, Sautebin L, Costantino G, Rombola L, Mazzon E, **Caputi AP**. Regulation of prostaglandin production by inhibition of poly (ADP-ribose) synthase in carrageenan-induced pleurisy. *Life Sci*. 1999; 65:1297-304.
213. Cuzzocrea S, De Sarro G, Costantino G, Ciliberto G, Mazzon E, De Sarro A, **Caputi AP**. IL-6 knock-out mice exhibit resistance to splanchnic artery occlusion shock. *J Leukoc Biol*. 1999; 66:471-80.
214. Cuzzocrea S, Costantino G, Mazzon E, **Caputi AP**. Protective effect of N-acetylcysteine on multiple organ failure induced by zymosan in the rat. *Crit Care Med*. 1999; 27:1524-32.
215. Cuzzocrea S, Zingarelli B, Costantino G, Sottile A, Teti D, **Caputi AP**. Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. *Crit Care Med*. 1999; 27:1517-23.
216. Cuzzocrea S, Costantino G, Zingarelli B, **Caputi AP**. Protective effects of poly (ADP-ribose) synthase inhibitors in zymosan-activated plasma induced paw edema. *Life Sci*. 1999; 65:957-64.
217. Calapai G, Crupi A, Firenzuoli F, Costantino G, Inferrera G, Campo GM, **Caputi AP**. Effects of *Hypericum perforatum* on levels of 5 -hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. *J Pharm Pharmacol*. 1999; 51:723-8.
218. Cuzzocrea S, Costantino G, Mazzon E, **Caputi AP**. Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. *J Pineal Res*. 1999; 27:9-14.
219. Cuzzocrea S, Costantino G, Mazzon E, Zingarelli B, De Sarro A, **Caputi AP**. Protective effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in paw oedema induced by carrageenan in the rat. *Biochem Pharmacol*. 1999; 58:171-6.
220. Cuzzocrea S, de Sarro G, Costantino G, Mazzon E, Laura R, Ciriaco E, de Sarro A, **Caputi AP**. Role of interleukin-6 in a non-septic shock model induced by zymosan. *Eur Cytokine Netw*. 1999;10:191-203.
221. Cuzzocrea S, Costantino G, Zingarelli B, Mazzon E, Micali A, **Caputi AP**. The protective role of endogenous glutathione in carrageenan-induced pleurisy in the rat. *Eur J Pharmacol*. 1999; 372:187-97.
222. Squadrito F, Altavilla D, Squadrito G, Ferlito M, Campo GM, Arlotta M, Grimaldi S, Quartarone C, Saitta A, **Caputi AP**. Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. *Br J Pharmacol*. 1999; 127:498-504.
223. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, **Caputi AP**. Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. *Br J Pharmacol*. 1999; 127:482-8.

224. Mazzaglia G, Arcoraci V, Greco S, Cucinotta G, Cazzola M, **Caputi AP**. Prescribing habits of general practitioners in choosing an empirical antibiotic regimen for lower respiratory tract infections in adults in Sicily. *Pharmacol Res.* 1999; 40:47-52.
225. Cutroneo P, Greco S, Cucinotta G, Arcoraci V, **Caputi AP**. Spontaneous reporting of adverse drug reactions in elderly patients in Sicily (Italy). *Pharmacol Res.* 1999; 40:41-6.
226. Altavilla D, Squadrito F, Campo GM, Squadrito G, Arlotta M, Urna G, Sardella A, Quartarone C, Saitta A, **Caputi AP**. The lazaroïd, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. *Eur J Pharmacol.* 1999; 369:49-55.
227. Cuzzocrea S, **Caputi AP**. Protective effect of melatonin on zymosan-induced cellular damage. *Biol Signals Recept.* 1999; 8:136-42.
228. Nava F, **Caputi AP**. Central effects of cromoglycate sodium salt in rats treated with lipopolysaccharide. *Eur J Pharmacol.* 1999; 367:351-9.
229. Cuzzocrea S, Costantino G, Mazzon E, **Caputi AP**. Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy. *Br J Pharmacol.* 1999; 126:407-14.
230. Cuzzocrea S, Costantino G, **Caputi AP**. Protective effect of N-acetylcysteine on cellular energy depletion in a non-septic shock model induced by zymosan in the rat. *Shock.* 1999; 11:143-8.
231. Squadrito F, Altavilla D, Squadrito G, Saitta A, Campo GM, Arlotta M, Quartarone C, Ferlito M, **Caputi AP**. Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. *Eur J Pharmacol.* 1999; 364:159-68.
232. Cuzzocrea S, Zingarelli B, Costantino G, **Caputi AP**. Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in carrageenan-induced pleurisy. *Free Radic Biol Med.* 1999; 26:25-33.
233. Costantino G, Cuzzocrea S, Mazzon E, **Caputi AP**. Protective effects of melatonin in zymosan-activated plasma-induced paw inflammation. *Eur J Pharmacol.* 1998; 363:57-63.
234. Calapai G, Marciano MC, Costantino G, Russo A, Corica F, Sautebin L, Di Rosa M, **Caputi AP**. Effects of water deprivation and angiotensin II intracerebroventricular administration on brain nitric oxide synthase activity. *Eur J Pharmacol.* 1998; 360:147-54.
235. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Minutoli L, Ferlito M, Saitta A, **Caputi AP**. Sulfatide reduces leucocyte accumulation and reverts vascular failure in splanchnic artery occlusion shock. *Eur J Pharmacol.* 1998; 361:101-8.
236. Calapai G, Corica F, Allegra A, Corsonello A, Sautebin L, De Gregorio T, Di Rosa M, Costantino G, Buemi M, **Caputi AP**. Effects of intracerebroventricular leptin administration on food intake, body weight gain and diencephalic nitric oxide synthase activity in the mouse. *Br J Pharmacol.* 1998; 125:798-802.
237. Cuzzocrea S, Costantino G, **Caputi AP**. Protective effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in a non-septic shock model induced by zymosan in the rat. *J Pineal Res.* 1998; 25:78-85.
238. Cuzzocrea S, Zingarelli B, **Caputi AP**. Role of peroxynitrite and poly (ADP-ribosyl) synthetase activation in cardiovascular derangement induced by zymosan in the rat. *Life Sci.* 1998; 63:923-33.

239. Cuzzocrea S, Zingarelli B, **Caputi AP**. Role of constitutive nitric oxide synthase and peroxynitrite production in a rat model of splanchnic artery occlusion shock. *Life Sci.* 1998; 63:789-99.
240. Campo GM, Squadrito F, Campo S, Altavilla D, Quartarone C, Ceccarelli S, Ferlito M, Avenoso A, Squadrito G, Saitta A, **Caputi AP**. Beneficial effect of raxofelast, a hydrophilic vitamin E analogue, in the rat heart after ischemia and reperfusion injury. *J Mol Cell Cardiol.* 1998; 30:1493-503.
241. Altavilla D, Squadrito F, Serrano M, Campo GM, Squadrito G, Arlotta M, Urna G, Sardella A, Saitta A, **Caputi AP**. Inhibition of tumour necrosis factor and reversal of endotoxin-induced shock by U-83836E, a second generation lazardoid, in rats. *Br J Pharmacol.* 1998; 124:1293-9.
242. Campo GM, Squadrito F, Campo S, Altavilla D, Longoni B, Saitta A, Squadrito G, **Caputi AP**. Protective effects of the new lazardoid, U-83836E, in splanchnic artery occlusion (SAO) shock. *Free Radic Res.* 1998; 28:477-84.
243. Cuzzocrea S, Zingarelli B, Costantino G, **Caputi AP**. Protective effect of melatonin in a non-septic shock model induced by zymosan in the rat. *J Pineal Res.* 1998; 25:24-33.
244. Mazzaglia G, Arcorac V, Cutroneo P, Inferrera S, Alecci U, Bonfiglio S, Marino S, Marino P, **Caputi AP**. [Infectious diseases in general practice and antibiotic prescription. Observational study in Sicily]. *Recenti Prog Med.* 1998; 89:356-60.
245. Spina E, Avenoso A, Facciola G, Fabrazzo M, Monteleone P, Maj M, Perucca E, **Caputi AP**. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. *Int Clin Psychopharmacol.* 1998; 13:141-5.
246. Cuzzocrea S, Zingarelli B, Villari D, **Caputi AP**, Longo G. Evidence for in vivo peroxynitrite production in human chronic hepatitis. *Life Sci.* 1998; 63:PL25-30.
247. Cutroneo PM, Arcoraci V, Cucinotta G, Inferrera G, Galante F, Sofia A, Ferrera E, Napolitano T, Mazzaglia G, **Caputi AP**. [Adverse drug reactions in childhood. A drug surveillance study in Sicily]. *Recenti Prog Med.* 1998; 89:290-5.
248. Mazzaglia G, Arcoraci V, Nicoletti G, **Caputi AP**. Pattern of antimicrobial drug prescribing and prescriptive behaviour for acute otitis media among physicians in Sicily. *Pharmacol Res.* 1998; 37:421-6.
249. Cuzzocrea S, Zingarelli B, **Caputi AP**. Peroxynitrate-mediated DNA strand breakage activates poly(ADP-ribose)synthetase and causes cellular energy depletion in a nonseptic shock model induced by zymosan in the rat. *Shock.* 1998; 9:336-40.
250. Cuzzocrea S, Zingarelli B, **Caputi AP**. Role of peroxynitrite and poly (ADP-ribose) synthetase on cellular energy depletion in carrageenan-induced pleurisy. *J Chemother.* 1998; 10:153-6.
251. Cuzzocrea S, **Caputi AP**, Zingarelli B. Peroxynitrite-mediated DNA strand breakage activates poly (ADP-ribose) synthetase and causes cellular energy depletion in carrageenan-induced pleurisy. *Immunology.* 1998; 93:96-101.
252. Mazzaglia G, Greco S, Lando C, Cucinotta G, **Caputi AP**. Adult acute upper respiratory tract infections in Sicily: pattern of antibiotic drug prescription in primary care. *J Antimicrob Chemother.* 1998; 41:259-66.
253. Campo GM, Squadrito F, Campo S, Altavilla D, Avenoso A, Ferlito M, Squadrito G, **Caputi AP**. Antioxidant activity of U-83836E, a second generation lazardoid, during myocardial ischemia/reperfusion injury. *Free Radic Res.* 1997; 27:577-90.

254. Greco S, Mazzaglia G, **Caputi AP**, Pagliaro L. Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics. *Ann Pharmacother.* 1997; 31:1548.
255. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Arcoraci V, Minutoli L, Serrano M, Saitta A, **Caputi AP**. 17Beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. *Eur J Pharmacol.* 1997; 335:185-92.
256. Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL, **Caputi AP**, Szabo C. Role of peroxynitrite and activation of poly (ADP-ribose) synthase in the vascular failure induced by zymosan-activated plasma. *Br J Pharmacol.* 1997; 122:493-503.
257. Cuzzocrea S, Zingarelli B, Sautebin L, Rizzo A, Crisafulli C, Campo GM, Costantino G, Calapai G, Nava F, Di Rosa M, **Caputi AP**. Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. *Shock.* 1997; 8:268-75.
258. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Arcoraci V, Minutoli L, Saitta A, **Caputi AP**. The involvement of tumour necrosis factor-alpha in the protective effects of 17 beta oestradiol in splanchnic ischaemia-reperfusion injury. *Br J Pharmacol.* 1997; 121:1782-8.
259. Nava F, Calapai G, Facciola G, Cuzzocrea S, Giuliani G, De Sarro A, **Caputi AP**. Melatonin effects on inhibition of thirst and fever induced by lipopolysaccharide in rat. *Eur J Pharmacol.* 1997;331:267-74.
260. Cuzzocrea S, Zingarelli B, Costantino G, Szabo A, Salzman AL, **Caputi AP**, Szabo C. Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. *Br J Pharmacol.* 1997; 121:1065-74.
261. Cuzzocrea S, Filippelli A, Zingarelli B, Falciani M, **Caputi AP**, Rossi F. Role of nitric oxide in a nonseptic shock model induced by zymosan in the rat. *Shock.* 1997; 7:351-7.
262. Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, **Caputi AP**. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. *Pharmacol Res.* 1997; 35:335-9.
263. Spina E, Avenoso A, Campo GM, Scordo MG, **Caputi AP**, Perucca E. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. *Br J Clin Pharmacol.* 1997; 43:315-8.
264. Nava F, Calapai G, Facciola G, Cuzzocrea S, Marciano MC, De Sarro A, **Caputi AP**. Effects of interleukin-10 on water intake, locomotory activity, and rectal temperature in rat treated with endotoxin. *Int J Immunopharmacol.* 1997; 19:31-8.
265. Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Serrano M, Minutoli L, Arlotta M, Musolino C, Saitta A, **Caputi AP**. Recombinant human granulocyte colony-stimulating factor reverts vascular dysfunction. *Int J Microcirc Clin Exp.* 1997; 17:10-4.
266. Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Ammedolia L, Arlotta M, Saitta A, **Caputi AP**. The effects of recombinant human granulocyte-colony stimulating factor on vascular dysfunction and splanchnic ischaemia-reperfusion injury. *Br J Pharmacol.* 1997; 120:333-9.
267. Spina E, Gitto C, Avenoso A, Campo GM, **Caputi AP**, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. *Eur J Clin Pharmacol.* 1997; 51:395-8.

268. Calapai G, Parente L, Nava F, Facciola G, Marciano MC, **Caputi AP**. Interleukin-1 inhibits drinking behaviour through prostaglandins, but not by nitric oxide formation. *Life Sci.* 1997; 60:457-64.
269. Cuzzocrea S, Zingarelli B, Calapai G, Nava F, **Caputi AP**. Zymosan-activated plasma induces paw oedema by nitric oxide and prostaglandin production. *Life Sci.* 1997; 60:215-20.
270. Squadrito F, Altavilla D, Ammendolia L, Squadrito G, Campo GM, Canale P, Ioculano M, Musolino C, Alonci A, Saitta A, Rossi F, **Caputi AP**. Leukocyte integrin very late antigen-4/vascular cell adhesion molecule-1 adhesion pathway in splanchnic artery occlusion shock. *Eur J Pharmacol.* 1996; 318:153-60.
271. Calapai G, **Caputi AP**. Nitric oxide and drinking behaviour. *Regul Pept.* 1996; 66:117-21.
272. Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Canale P, Rossi F, Saitta A, **Caputi AP**. Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock. *Br J Pharmacol.* 1996; 119:23-8.
273. Nava F, Calapai G, De Sarro A, **Caputi AP**. Interleukin-1 receptor antagonist does not reverse lipopolysaccharide-induced inhibition of water intake in rat. *Eur J Pharmacol.* 1996; 309:223-7.
274. Altavilla D, Squadrito F, Ammendolia L, Squadrito G, Campo GM, Canale P, Ioculano M, Musolino C, Alonci A, Sardella A, Urna G, Saitta A, **Caputi AP**. Monocytes and lymphocytes as active participants in the pathogenesis of experimental shock. *Inflamm Res.* 1996; 45:398-404.
275. Calapai G, Mazzaglia G, Sautebin L, Costantino G, Marciano MC, Cuzzocrea S, Di Rosa M, **Caputi AP**. Inhibition of nitric oxide formation reduces voluntary ethanol consumption in the rat. *Psychopharmacology (Berl).* 1996; 125:398-401.
276. Campo GM, Squadrito F, Altavilla D, Squadrito G, Avenoso A, Canale P, Ioculano M, Sperandeo A, **Caputi AP**. Protection of ischemic and reperfused rat myocardium by the nonglucocorticoid 21-aminosteroid U-74389G, a new inhibitor of lipid peroxidation. *J Pharmacol Exp Ther.* 1996; 277:333-40.
277. Altavilla D, Squadrito F, Canale P, Ioculano M, Campo GM, Squadrito G, Urna G, Sardella A, **Caputi AP**. Endotoxin tolerance impairs a pertussis-toxin-sensitive G-protein regulating tumour necrosis factor release by macrophages from tumour-bearing rats. *Pharmacol Res.* 1996; 33:203-9.
278. Spina E, Avenoso A, Campo GM, **Caputi AP**, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. *Ther Drug Monit.* 1996; 18:60-4.
279. Saitta A, Bonaiuto M, Giordano G, Saitta MN, Castaldo M, Cinquegrani M, Squadrito G, Canale P, Altavilla D, Campo GM, **Caputi AP**, Squadrito F. Effects of cloricromene on the levels of endothelin and on the microcirculatory function in peripheral atherosclerotic arteriopathies. *Pharmacology.* 1996; 52:8-15.
280. Squadrito F, Saitta A, Altavilla D, Ioculano M, Canale P, Campo GM, Squadrito G, Di Tano G, Mazzu A, **Caputi AP**. Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. *Inflamm Res.* 1996; 45:14-9.
281. Squadrito F, Altavilla D, Ammendolia L, Squadrito G, Campo GM, Sperandeo A, Canale P, Ioculano M, Saitta A, **Caputi AP**. Improved survival and reversal of endothelial dysfunction by the 21-aminosteroid, U-74389G in splanchnic ischaemia-reperfusion injury in the rat. *Br J Pharmacol.* 1995; 115:395-400.
282. Ioculano M, Altavilla D, Squadrito F, Canale P, Squadrito G, Saitta A, Campo GM, **Caputi AP**. Tumour necrosis factor mediates E-selectin production and leukocyte accumulation in myocardial ischaemia-reperfusion injury. *Pharmacol Res.* 1995; 31:281-8.



283. Altavilla D, Squadrito F, Canale P, Iocolano M, Campo GM, Squadrito G, Saitta A, **Caputi AP**. Tumor necrosis factor induces E-selectin production in splanchnic artery occlusion shock. *Am J Physiol*. 1995; 268:H1412-7.
284. Squadrito F, Altavilla D, Iocolano M, Canale P, Campo GM, Squadrito G, Ditano G, Freni F, Saitta A, **Caputi AP**. Soluble E-selectin levels in acute human myocardial infarction. *Int J Microcirc Clin Exp*. 1995; 15:80-4.
285. Calapai G, Squadrito F, Rizzo A, Marciano MC, Campo GM, **Caputi AP**. Multiple actions of the coumarine derivative cloricromene and its protective effects on ischemic brain injury. *Naunyn Schmiedebergs Arch Pharmacol*. 1995; 351:209-15.
286. Zingarelli B, Halushka PV, **Caputi AP**, Cook JA. Increased nitric oxide synthesis during the development of endotoxin tolerance. *Shock*. 1995; 3:102-8.
287. Spina E, Avenoso A, Campo GM, **Caputi AP**, Perucca E. The effect of carbamazepine on the 2-hydroxylation of desipramine. *Psychopharmacology (Berl)*. 1995; 117:413-6.
288. Altavilla D, Squadrito F, Canale P, Iocolano M, Campo GM, Squadrito G, Ammendolia L, **Caputi AP**. E-selectin involvement in the pathogenesis of splanchnic artery occlusion shock. *Eur J Pharmacol*. 1995; 272:223-9.
289. Zingarelli B, Chen H, **Caputi AP**, Halushka PV, Cook JA. Reorientation of macrophage mediator production in endotoxin tolerance. *Prog Clin Biol Res*. 1995; 392:529-37.
290. Canale P, Squadrito F, Altavilla D, Iocolano M, Campo GM, Squadrito G, Urna G, Sardella A, **Caputi AP**. Beneficial effects of BAY u3405, a novel thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock. *Pharmacology*. 1994; 49:376-85.
291. Squadrito F, Altavilla D, Canale P, Iocolano MP, Campo GM, Ammendolia L, Squadrito G, Saitta A, Calapai G, **Caputi AP**. Contribution of intercellular adhesion molecule 1 (ICAM-1) to the pathogenesis of splanchnic artery occlusion shock in the rat. *Br J Pharmacol*. 1994; 113:912-6.
292. Iocolano M, Squadrito F, Altavilla D, Canale P, Squadrito G, Campo GM, Saitta A, **Caputi AP**. Antibodies against intercellular adhesion molecule 1 protect against myocardial ischaemia-reperfusion injury in rat. *Eur J Pharmacol*. 1994; 264:143-9.
293. Canale P, Squadrito F, Altavilla D, Iocolano M, Zingarelli B, Campo GM, Urna G, Sardella A, Squadrito G, **Caputi AP**. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. *Agents Actions*. 1994; 42:128-34.
294. Spina E, Ancione M, Di Rosa AE, Artemisia A, Natoli C, **Caputi AP**. Iron status in schizophrenic patients with acute neuroleptic-induced dystonic reactions. *Prog Neuropsychopharmacol Biol Psychiatry*. 1994; 18:891-8.
295. Zingarelli B, **Caputi AP**, Di Rosa M. Dexamethasone prevents vascular failure mediated by nitric oxide in hemorrhagic shock. *Shock*. 1994; 2:210-5.
296. Spina E, Avenoso A, Campo GM, **Caputi AP**, Perucca E. Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. *Ther Drug Monit*. 1994; 16:432-4.

297. Altavilla D, Canale P, Squadrito F, Sardella A, Ammendolia L, Urna G, Ioculano M, Squadrito G, **Caputi AP**. Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock. *Pharmacol Res.* 1994; 30:137-51.
298. Zingarelli B, Squadrito F, Altavilla D, Calapai G, Di Rosa M, **Caputi AP**. Role of tumor necrosis factor- $\alpha$  in acute hypovolemic hemorrhagic shock in rats. *Am J Physiol.* 1994; 266:H1512-5.
299. Spina E, Campo GM, Avenoso A, **Caputi AP**, Zuccaro P, Pacifici R, Gatti G, Strada G, Bartoli A, Perucca E. CYP2D6-related oxidation polymorphism in Italy. *Pharmacol Res.* 1994; 29:281-9.
300. Calapai G, Mazzaglia G, Cilia M, Zingarelli B, Squadrito F, **Caputi AP**. Mediation by nitric oxide formation in the preoptic area of endotoxin and tumour necrosis factor-induced inhibition of water intake in the rat. *Br J Pharmacol.* 1994; 111:1328-32.
301. Campo GM, Squadrito F, Ioculano M, Altavilla D, Calapai G, Zingarelli B, Scuri R, **Caputi AP**. Reduction of myocardial infarct size in rat by IRFI-048, a selective analogue of vitamin E. *Free Radic Biol Med.* 1994; 16: 427-35.
302. Squadrito F, Calapai G, Altavilla D, Cucinotta D, Zingarelli B, Arcoraci V, Campo GM, **Caputi AP**. Central serotonergic system involvement in the anorexia induced by NG-nitro-L-arginine, an inhibitor of nitric oxide synthase. *Eur J Pharmacol.* 1994; 255:51-5.
303. Zingarelli B, Squadrito F, Bussolino F, Calapai G, Altavilla D, Ioculano M, Campo GM, Canale P, **Caputi AP**. Evidence for a role of platelet activating factor in hypovolemic shock in the rat. *J Lipid Mediat Cell Signal.* 1994; 9:123-34.
304. Spina E, **Caputi AP**. Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. *Pharmacol Res.* 1994; 29:121-37.
305. Altavilla D, Squadrito F, Ioculano M, Canale P, Campo GM, Zingarelli B, **Caputi AP**. E-selectin in the pathogenesis of experimental myocardial ischemia-reperfusion injury. *Eur J Pharmacol.* 1994; 270:45-51.
306. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, **Caputi AP**. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. *Int Clin Psychopharmacol.* 1994; 9:281-5.
307. Squadrito F, Calapai G, Altavilla D, Cucinotta D, Zingarelli B, Campo GM, Arcoraci V, Sautebin L, Mazzaglia G, **Caputi AP**. Food deprivation increases brain nitric oxide synthase and depresses brain serotonin levels in rats. *Neuropharmacology.* 1994; 33:83-6.
308. Ioculano M, Squadrito F, Altavilla D, Canale P, Campo GM, Bussolino F, Sardella A, Urna G, **Caputi AP**. Protective effects of L-659,989, a platelet-activating factor receptor antagonist, in myocardial ischemia and reperfusion in rats. *J Cardiovasc Pharmacol.* 1994; 23:7-12.
309. Squadrito F, Ioculano M, Altavilla D, Zingarelli B, Canale P, Campo GM, Saitta A, Oriti S, Spignoli G, **Caputi AP**. G619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in rats. *Pharmacology.* 1993; 47:167-75.
310. Squadrito F, Ioculano M, Altavilla D, Zingarelli B, Canale P, Campo GM, Saitta A, Calapai G, Bussolino F, **Caputi AP**. Platelet activating factor interaction with tumor necrosis factor in myocardial ischaemia-reperfusion injury. *J Lipid Mediat.* 1993; 8:53-65.

311. Squadrito F, Ioculano M, Altavilla D, Zingarelli B, Canale P, Campo GM, Saitta A, Oriti S, Faggiotto A, **Caputi AP**. Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury. *Agents Actions*. 1993; 39:143-9.
312. Zingarelli B, Squadrito F, Graziani P, Camerini R, **Caputi AP**. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. *Agents Actions*. 1993; 39:150-6.
313. Squadrito F, Altavilla D, Zingarelli B, Ioculano M, Calapai G, Campo GM, Miceli A, **Caputi AP**. Tumor necrosis factor involvement in myocardial ischaemia-reperfusion injury. *Eur J Pharmacol*. 1993; 237:223-30.
314. Spina E, Avenoso A, Pollicino AM, **Caputi AP**, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine or fluvoxamine. *Ther Drug Monit*. 1993; 15:247-50.
315. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, **Caputi AP**. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. *Ther Drug Monit*. 1993; 15:243-6.
316. Squadrito F, Calapai G, Cucinotta D, Altavilla D, Zingarelli B, Ioculano M, Urna G, Sardella A, Campo GM, **Caputi AP**. Anorectic activity of NG-nitro-L-arginine, an inhibitor of brain nitric oxide synthase, in obese Zucker rats. *Eur J Pharmacol*. 1993; 230:125-8.
317. Canale P, Squadrito F, Zingarelli B, Altavilla D, Ioculano M, Campo GM, **Caputi AP**. Splanchnic artery occlusion shock: vinblastine-induced leukopenia reduces tumour necrosis factor and thromboxane A2 formation, and increases survival rate. *Pharmacol Res*. 1993;27:61-71.
318. Squadrito F, Altavilla D, Zingarelli B, Ioculano M, Calapai G, Campo GM, Miceli A, Prosdocimi M, **Caputi AP**. The effect of cloricromene, a coumarine derivative, on leukocyte accumulation, myocardial necrosis and TNF-alpha production in myocardial ischaemia-reperfusion injury. *Life Sci*. 1993; 53: 341-55.
319. Squadrito F, Saitta A, Altavilla D, Campo GM, Ioculano M, Squadrito G, **Caputi AP**. [Tumor necrosis factor in myocardial ischemia and reperfusion] *Cardiologia*. 1993 ;38:45-51.
320. Spina E, Pollicino AM, Avenoso A, Campo GM, **Caputi AP**. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. *Int J Clin Pharmacol Res*. 1993; 13:167-71.
321. Spina E, Sturiale V, Valvo S, Ancione M, Di Rosa AE, Meduri M, **Caputi AP**. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. *Int Clin Psychopharmacol*. 1993;8:21-4.
322. Zingarelli B, Squadrito F, Ioculano M, Altavilla D, Bussolino F, Campo GM, **Caputi AP**. Platelet activating factor interaction with tumor necrosis factor and myocardial depressant factor in splanchnic artery occlusion shock. *Eur J Pharmacol*. 1992; 222:13-9.
323. Spina E, Sturiale V, Valvo S, Ancione M, Di Rosa AE, Meduri M, **Caputi AP**. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. *Acta Psychiatr Scand*. 1992; 86:364-6.
324. Calapai G, Altavilla D, Marciano MC, Mazzaglia G, Cilia M, Squadrito F, **Caputi AP**. Nitric oxide (NO) mediates antidipsogenic action of Escherichia coli endotoxin (LPS) and tumor necrosis factor (TNF-alpha) in the rat. *Pharmacol Res*. 1992; 26:166-7.
325. Altavilla D, Urna G, Sardella A, Squadrito F, Calapai G, Campo GM, **Caputi AP**. Protective effects of endotoxin tolerance in tumor bearing rats. *Pharmacol Res*. 1992; 26:162-3.

326. **Caputi AP**, Squadrito F. Role of TNF-alpha and therapeutic perspectives in bowel and myocardial ischemia/reperfusion injury. *Pharmacol Res.* 1992; 26:150-1.
327. Calapai G, Squadrito F, Altavilla D, Zingarelli B, Campo GM, Cilia M, **Caputi AP**. Evidence that nitric oxide modulates drinking behaviour. *Neuropharmacology.* 1992; 31:761-4.
328. Squadrito F, Altavilla D, Ioculano M, Calapai G, Zingarelli B, Saitta A, Campo GM, Rizzo A, **Caputi AP**. Passive immunization with antibodies against tumor necrosis factor (TNF-alpha) protects from the lethality of splanchnic artery occlusion shock. *Circ Shock.* 1992; 37:236-44.
329. Campo GM, Squadrito F, Ioculano M, Avenoso A, Zingarelli B, Calandra S, Scuri R, Saitta A, **Caputi AP**. IRFI-016, a new radical scavenger, limits ischemic damage following coronary artery occlusion in rats. *Res Commun Chem Pathol Pharmacol.* 1992; 76:287-303.
330. Spina E, Campo GM, Avenoso A, Pollicino MA, **Caputi AP**. Interaction between fluvoxamine and imipramine/desipramine in four patients. *Ther Drug Monit.* 1992; 14:194-6.
331. Zingarelli B, Squadrito F, Altavilla D, Calapai G, Campo GM, Calo M, Saitta A, **Caputi AP**. Evidence for a role of nitric oxide in hypovolemic hemorrhagic shock. *J Cardiovasc Pharmacol.* 1992; 19:982-6.
332. Squadrito F, Macchiarelli G, Santoro G, Arcoraci V, Trimarchi GR, Sturniolo R, Nottola SA, Motta PM, **Caputi AP**. Effects of captopril on the development of rat doxorubicin nephropathy. *Histol Histopathol.* 1992; 7:223-9.
333. Squadrito F, Altavilla D, Campo GM, Calapai G, Ioculano M, Zingarelli B, Saitta A, Prosdocimi M, **Caputi AP**. Cloricromene, a coumarine derivative, protects against lethal endotoxin shock in rats. *Eur J Pharmacol.* 1992; 210:107-13.
334. Spina E, Campo GM, Calandra S, **Caputi AP**, Carrillo JA, Benitez J. Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients. *Pharmacol Res.* 1992; 25:43-50.
335. Calapai G, Mazzaglia G, Marciano MC, Squadrito F, Altavilla D, Zingarelli B, Prosdocimi M, **Caputi AP**. Cloricromene antagonizes antidipsogenic effects induced by endotoxin, but not by TNF alpha, in the rat. *Life Sci.* 1992; 51:2041-8.
336. Spina E, Ancione M, Di Rosa AE, Meduri M, **Caputi AP**. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. *Eur J Clin Pharmacol.* 1992; 42:347-8.
337. Sturniolo R, Squadrito F, Campo GM, Vinci R, Calatroni A, Prosdocimi M, **Caputi AP**. Protective effect of cloricromene, a coumarine derivative, in hypovolemic hemorrhagic shock in the rat. *J Cardiovasc Pharmacol.* 1991; 17:261-6.
338. Squadrito F, Sturniolo R, Altavilla D, Santoro G, Campo GM, Arena A, **Caputi AP**. Platelet activating factor involvement in splanchnic artery occlusion shock in rats. *Eur J Pharmacol.* 1991; 192:47-53.
339. Trimarchi GR, Germano A, Campo GM, De Luca R, **Caputi AP**. Changes in urine volume and urinary electrolyte excretion after intracerebroventricular injection of arecoline and hemicholinium-3. *Life Sci.* 1991; 48:2097-107.
340. Spina E, Martines C, **Caputi AP**, Cobaleda J, Pinas B, Carrillo JA, Benitez J. Debrisoquine oxidation phenotype during neuroleptic monotherapy. *Eur J Clin Pharmacol.* 1991; 41:467-70.

341. Trimarchi GR, De Luca R, Campo GM, Scuri R, **Caputi AP**. Protective effects of fructose-1,6-bisphosphate on survival and brain putrescine levels during ischemia and recirculation in the Mongolian gerbil. *Stroke*. 1990; 21:171-3.
342. Squadrito F, Sturniolo R, Altavilla D, Seminara S, **Caputi AP**. Effects of L-652,731, a platelet activating factor (PAF) receptor antagonist, in splanchnic artery occlusion (SAO) shock in rats. *Pharmacol Res*. 1990; 22:53-4.
343. Crescimanno M, D'Alessandro ND, Armata MG, Sturniolo R, **Caputi AP**. Influence of fructose 1,6-diphosphate on the lung antioxidant defenses of mice with endotoxemia. *Pharmacol Res*. 1990;22:74-5.
344. Squadrito F, Sturniolo R, Altavilla D, **Caputi AP**. Evidences for a role of tumor necrosis factor (TNF) in splanchnic artery occlusion shock in the rat. *Pharmacol Res*. 1990; 22:68-9.
345. Squadrito F, Buemi AL, Sturniolo R, Buemi M, Corica F, Frisina N, Squadrito G, **Caputi AP**. Effects of intracerebroventricular administration of magnesium sulphate on blood pressure and heart rate in anesthetized normotensive and hypertensive rats. *Jpn J Pharmacol*. 1990; 53:495-8.
346. Calapai G, Squadrito F, Massi M, **Caputi AP**, de Caro G. Endotoxin inhibition of drinking behaviour in the rat. *Pharmacol Res*.1990; 22:161-70.
347. D'Avella D, Germano A, Santoro G, Costa G, Zuccarello M, **Caputi AP**, Hayes RL, Tomasello F. Effect of experimental subarachnoid hemorrhage on CSF eicosanoids in the rat. *J Neurotrauma*. 1990; 7:121-9.
348. Squadrito F, Sturniolo R, Trimarchi GR, Campo GM, De Luca G, Gorini A, **Caputi AP**. Antihypertensive activity of indolepyruvic acid: a keto analogue of tryptophan. *J Cardiovasc Pharmacol*. 1990; 15:102-8.
349. Squadrito F, Sturniolo R, Altavilla D, Campo GM, Trimarchi GR, Scuri R, **Caputi AP**. Effects of fructose 1,6-diphosphate on splanchnic artery occlusion shock in the rat. *Resuscitation*. 1989; 18:299-307.
350. Trimarchi GR, Campo GM, **Caputi AP**. Changes in urinary output after depletion of cerebral acetylcholine stores in the rat. *Pharmacol Res*. 1989; 21:29-30.
351. Squadrito F, Sturniolo R, Altavilla D, **Caputi AP**. AD6, a coumarin derivative, and other pharmacological approaches to splanchnic artery occlusion (SAO) shock therapy. *J Chemother*. 1989; 1:473-5.
352. Sturniolo R, Squadrito F, Altavilla D, Trimarchi GR, Prosdociami M, **Caputi AP**. Cloricromene improves survival rate and peritoneal macrophage function in splanchnic artery occlusion shock in rats. *Circ Shock*. 1989; 28:267-77.
353. Squadrito F, Frisina N, Buemi M, Sturniolo R, Autolitano A, Magri V, Squadrito G, **Caputi AP**. A comparison of synthetic human and rat ANP administered intracerebroventricularly in freely moving normotensive and hypertensive rats. *J Cardiovasc Pharmacol*. 1989; 13: S27-30.
354. Squadrito F, Sturniolo R, Arcadi F, Arcoraci V, **Caputi AP**. Evidence that a GABAergic mechanism influences the development of obesity in obese Zucker rats. *Pharmacol Res Commun*. 1988; 20:1087-8.
355. Spina E, Buemi AL, **Caputi AP**, Benitez J, Cobaleda J, Garcia MA, Llerena A, Pina B. Debrisoquine oxidation in schizophrenic patients treated with neuroleptics. *Pharmacol Res Commun*. 1988; 20:1103-4.
356. Sturniolo R, Altavilla D, Berlinghieri MC, Squadrito F, **Caputi AP**. Splanchnic artery occlusion shock in the rat: effects of the calcium entry blockers nimodipine and verapamil. *Circ Shock*. 1988; 24:43-53.

357. Trimarchi GR, Squadrito F, Magri V, Ientile R, Costa G, **Caputi AP**. Cerebral GABAergic control of arterial blood pressure and heart rate in diabetic rats. *Res Commun Chem Pathol Pharmacol*. 1987; 58:307-21.
358. Squadrito F, Calapai G, Autolitano A, Frisina N, Santoro G, Buemi M, Squadrito G, **Caputi AP**. Central dipsogenic effect of synthetic rat atrial natriuretic polypeptide in normotensive rats. *Jpn J Pharmacol*. 1987; 45:567-9.
359. Aragona P, Candela V, **Caputi AP**, Micali A, Puzzolo D, Quintieri M. Effects of a stable analogue of PGE<sub>2</sub> (11-deoxy-13,14-didehydro-16 (S)-methyl ester methyl PGE<sub>2</sub>: FCE 20700) on the secretory processes of conjunctival goblet cells of rabbit. *Exp Eye Res*. 1987; 45:647-54.
360. Squadrito F, Trimarchi GR, Lupica S, Magri V, Costa G, Brezenoff HE, **Caputi AP**. Cerebral cholinergic control of rat arterial blood pressure in streptozotocin-induced diabetes. *Pharmacol Res Commun*. 1986; 18:951-65.
361. Ruggeri P, Saija A, Costa G, **Caputi AP**. Influence of several aldehyde dehydrogenase and aldehyde reductase inhibitors on diamine oxidase in rat brain. *Res Commun Chem Pathol Pharmacol*. 1986;51:205-9.
362. Squadrito F, Quattrone G, Buemi M, Frisina N, **Caputi AP**, Squadrito G. Role of brain cholinergic system in the antihypertensive effect of clonidine in different models of rat hypertension. *J Hypertens Suppl*. 1985; 3:S97-9.
363. Padovano I, Matera G, De Pasquale R, Costa G, **Caputi AP**. Effect of intracerebroventricular injection of pentagastrin on rat drinking behavior. *Pol J Pharmacol Pharm*. 1985; 37:495-501.
364. Foca A, Matera G, Mastroeni P, **Caputi AP**. Evidence that prostaglandins within preoptic area (POA) may mediate the antidipsogenic effect of Escherichia coli endotoxin in the rat. *Circ Shock*. 1985; 17:137-45.
365. Costa G, Saija A, Padovano I, Trimarchi GR, De Pasquale R, **Caputi AP**. The calcium antagonist nimodipine increases beta-endorphin release from rat hypophysis through an action on adrenal glands. An in vivo and in vitro study. *Pharmacol Res Commun*. 1984; 16:959-68.
366. Saija A, Mondello F, Trimarchi GR, Foca A, Costa G, Mastroeni P, **Caputi AP**. Shigella sonnei endotoxin reduces arterial blood pressure but does not alter pituitary pro-opiocortin cleavage and corticosterone release in the rat. *Res Commun Chem Pathol Pharmacol*. 1984; 45:313-6.
367. Magri V, Trimarchi GR, Quattrone G, Squadrito F, Di Giorgio RM, Costa G, **Caputi AP**. Increased cardiovascular responsiveness to GABAergic stimulation in DOCA-salt hypertensive rats. *Res Commun Chem Pathol Pharmacol*. 1984; 45:107-18.
368. D'Avella D, Ciccirello R, La Torre F, Princi P, Greenberg RP, D'Aquino S, **Caputi AP**. The effect of the calcium antagonist nimodipine upon local cerebral glucose utilization in the rat brain. *Life Sci*. 1984; 34:2583-8.
369. Germano D, Pochiero M, Romeo G, Nunziata A, Costa G, **Caputi AP**. Cadmium alters arterial baroreflex control of heart rate in the conscious rat. *Arch Toxicol Suppl*. 1984; 7:374-7.
370. Focà A, Matera G, Chisari M, Mastroeni P, **Caputi AP**. Effects of different bacterial endotoxins on the drinking behaviour of the rat. *G Bacteriol Virol Immunol*. 1984; 77:9-18.
371. Nicoletta P, Pochiero M, Losi E, **Caputi AP**. Interaction between renin-angiotensin system and cholinergic system in brain. *Neuropharmacology*. 1983; 22:1269-75.

372. Foca A, Altavilla D, Mondello F, Nicoletta P, Miragliotta G, Mastroeni P, **Caputi AP**. Cardiovascular responses of conscious rats to acute intravenous and intracerebroventricular administration of *Shigella sonnei* endotoxin. *Res Commun Chem Pathol Pharmacol*. 1983; 42:213-22.
373. Costa G, Saija A, **Caputi AP**. Effect of nimodipine, a new calcium antagonist, on ACTH and corticosterone release "in vivo" and "in vitro". *Res Commun Chem Pathol Pharmacol*. 1983 41:355-67. PMID: 6314455.
374. Pochiero M, Nicoletta P, Losi E, Bianchi A, **Caputi AP**. Cardiovascular responses of conscious DOCA-salt hypertensive rats to acute intracerebroventricular and intravenous administration of captopril. *Pharmacol Res Commun*. 1983; 15:173-82.
375. Altavilla D, Losi E, Foca A, **Caputi AP**, Mastroeni P. [Bacterial lipopolysaccharides: comparative analysis of the cardiovascular effects of *E. coli*, *S. sonnei* and *Y. enterocolitica* in anesthetized rats] *G Bacteriol Virol Immunol*. 1983; 76:20-4.
376. Foca A, Nicoletta P, Matera G, Mastroeni P, **Caputi AP**. Antidipsogenic effect of endotoxin in the rat. *Circ Shock*. 1983; 11:341-50.
377. Foca A, Altavilla D, Mondello F, Fumarola D, **Caputi AP**. Cardiovascular effects of *Shigella sonnei* endotoxin in the rat. *Res Commun Chem Pathol Pharmacol*. 1982; 38:221-33.
378. Rotiroti D, Palella B, Losi E, Nistico G, **Caputi AP**. Evidence that a GABAergic mechanism influences the development of DOCA-salt hypertension in the rat. *Eur J Pharmacol*. 1982; 83:153-4.
379. **Caputi AP**, Rossi F, Carney K, Brezenoff HE. Modulatory effect of brain acetylcholine on reflex-induced bradycardia and tachycardia in conscious rats. *J Pharmacol Exp Ther*. 1980; 215:309-16.
80. **Caputi AP**, Camilleri BH, Brezenoff HE. Age-related hypotensive effect of atropine in unanesthetized spontaneously hypertensive rats. *Eur J Pharmacol*. 1980; 66:103-9.
381. Brezenoff HE, **Caputi AP**. Intracerebroventricular injection of hemicholinium-3 lowers blood pressure in conscious spontaneously hypertensive rats but not in normotensive rats. *Life Sci*. 1980; 26:1037-45.
382. **Caputi AP**, Brezenoff HE. Cardiovascular effects produced by choline injected into the lateral cerebral ventricle of the unanesthetized rat. *Life Sci*. 1980; 26:1029-36.
383. Marmo E, Rossi F, Lampa E, Giordano L, **Caputi AP**, Vacca C, Ariello B, Rosatti F. Cardiovascular research on PGI<sub>2</sub>, 6-keto-PGF<sub>1</sub> alpha, PGF<sub>2</sub> alpha, and 15(S)-15-methyl-PGF<sub>2</sub> alpha. *Adv Prostaglandin Thromboxane Res*. 1980; 7:701-9.
384. Abignente E, Arena F, Carola M, de Caprariis P, **Caputi AP**, Rossi F, Giordano L, Vacca C, Lampa E, Marmo E. [Research on heterocyclic compounds. VIII. Heteroarylcarboxamides and-acetamides with antipyretic activity] *Farmaco [Sci]*. 1979; 34:417-32.
385. Marmo E, Rossi F, **Caputi AP**, Lampa E, Petrarca R, Ottavo R. [Indoramin, a drug with prevalent antihypertensive activity: experimental study. *Clin Ter*. 1979; 88:233-62.
386. **Caputi AP**, Rossi F, Lampa E, Imperatore A, Visone C, Marmo E. [Mexiletine, a drug with anti-arrhythmic action. Experimental research on the cardiovascular system] *Arch Sci Med* 1979;136:1-15.
387. Marmo E, **Caputi AP**, Nistico GM, Rossi F, Lampa E. Effects of clenbuterol on bronchial, cardiac and hypothalamic adenylate cyclase. *Res Commun Chem Pathol Pharmacol*. 1979; 23:3-9.

388. **Caputi AP**, Rossi F, Vacca C, Ottavo R, Somma A, Sasso M, Marmo E. [Phosphorylcholine and cell membranes] *Boll Chim Farm.* 1978;117:553-9.
389. **Caputi AP**, Russo G, Scafuro MA, Turtur A, Lampa E, Sannino A, Nunziata A. [Experimental analysis of interference between alpha-adrenergic stimulants with anti-hypertensive activity and the narcotic activity of pentobarbital] *Arch Sci Med* 1978; 135:351-8.
390. Caputi AP, Lampa E, Rossi F, Nistico G, Marmo E. Activation of histamine H<sub>2</sub>-receptors by St 600. *Agressologie.* 1978; 19:35-7.
391. **Caputi AP**, Rossi F, Lampa E, Vacca C, Giordano L, Marmo E. The effect of beta-adrenergic blocking agents on DOCA-induced hypertensive state in rats. *Agressologie.* 1978; 19:325-30.
392. Marmo E, Lampa E, Rossi F, **Caputi AP**, Chieppa S, Vacca C, Giordano L, Pedone P. [Experimental studies of the specificity and aspecificity of a beta-adrenolytic agent, bunitrolol (Ko 1366)]. *Arch Sci Med* 1978; 135:15-56.
393. Catena E, Marmo E, Marcatili S, **Caputi AP**. [Anatomic and early functional changes in the tracheo-bronchial tree after inhalation of various exogenous substances. Experimental studies] *Bronchopneumologie.* 1977; 27:154-68.
394. Marmo E, **Caputi AP**, Rossi F, Lampa E, Giordano L, Accarino G. Experimental analysis of some cardiovascular effects of St 600, clonidine (St 155) and guanabenz (BR 750). *Agressologie.* 1977; 18:190-200.
395. Catena E, Marmo E, Caputi M, **Caputi AP**. [Experimental studies on the tracheobronchial reactivity in animals with exogenous pollutants] *Bronchopneumologie.* 1976;26:317-21.
396. Marmo E, Lampa E, **Caputi AP**, Rossi F, Di Nola R, Saini RK, Vacca C, Giordano L, Scafuro MA. Experimental analysis of the specific and aspecific activity of tolamolol (dl-UK 6558). *Agressologie.* 1976; 17:361-78.
397. Marmo E, Catena E, Rossi F, Caputi AP, Caputi M. Respiratory and cardiovascular effects by inhalation of PGF<sub>2</sub>alpha and PGE<sub>1</sub> in laboratory animals. *Agressologie.* 1976; 17:225-36.
398. Marmo E, **Caputi AP**, Rossi F, Lampa E, Vacca C, Brita G, Saini RK, Di Nola R. Experimental analysis of anti-hypertensive effects of beta-adrenergic blocking agents. *Agressologie.* 1976; 17:279-95.
399. Marmo E, Imperatore A, Cazzola M, Vacca C, **Caputi AP**. [Activity against clotting and platelet aggregation of the anticoagulant fraction of venom from *Agkistrodon rhodostoma*]. *Clin Ter.* 1975; 75:117-39.
400. Marmo E, Saini RK, Lampa E, **Caputi AP**, Cazzola M, Rossi F. PGF<sub>2</sub>alpha and nictitating membrane: an experimental study in vivo and in vitro. *Farmaco [Prat].* 1975; 30:291-301.
401. Marmo E, Coscia L, Rossi F, Chieppa S, Brita G, **Caputi AP**. [Experimental analysis of some cardiovascular effects of Verapamil] *Minerva Med.* 1975;66:1771-826.
402. Marmo E, Lampa E, Vacca C, Saini RK, **Caputi AP**. Experimental analysis of some cardiac effects of PGF<sub>2</sub>alpha on various animals. *Farmaco [Prat].* 1974; 29:671-713.
403. Marmo E, **Caputi AP**, Rossi F, Saini RK, Vacca C, Di Nola R. Experimental analysis of some vascular and respiratory effects of PGF<sub>2</sub>alpha on various animals. *Farmaco [Prat].* 1974;29:523-85.



404. Marmo E, Saini RK, **Caputi AP**. Bamethan A competitive betamimetic drug. *ResCommun Chem Pathol Pharmacol*. 1974; 8:247-72.
405. Marmo E, **Caputi AP**, Vacca C, Imperatore A, Cataldi S. [Cholesterol and lipid lowering effects and vascular action of p-chlororphenoxy-alpha-isobutyrate of 3-hydroxymethyl-pyridine-hydrochloric acid (clofinol)] *Clin Ter*. 1974; 68:519-67.
406. Marmo E, Mastrantonio P, **Caputi AP**, Rossi F. [Prostaglandin F2alpha and the uterine musculature: bibliographic review and experimental contribution] *Arch Ostet Ginecol*. 1974; 79:1-163.
407. Marmo E, Vacca C, Cataldi S, **Caputi AP**. Cardiac histological and serum-biochemical changes produced by isoprenaline and terbutaline in the pigeon. *J Med*. 1974; :244-57.
408. Saini RK, Rossi F, **Caputi AP**, Marmo E. Effects of BR 750 (2,6-dichlorobenzylideneaminoguanidine acetate) on cardiac and some smooth muscles. An in vitro experimental study. *Farmaco [Prat]*. 1973; 28:642-58.
409. Marmo E, Saini RK, **Caputi AP**, Vacca C. Cardiovascular profile of BR750 (2,6-dichloro-benzylideneamino-guanidine acetate). *Res Commun Chem Pathol Pharmacol*. 1973; 6:391-406.
410. Saini RK, **Caputi AP**, Marmo E. Cardiovascular profile of BR 750 (2,6-dichlorobenzylideneaminoguanidine acetate). *Farmaco [Prat]*.1973; 28:359-87.
411. Marmo E, Caputi AP, Saini RK. Cardiac histological and serum-biochemical changes produced by various adrenergic stimulant drugs in the rat. *Basic Res Cardiol*. 1973; 68:318-34.
412. Marmo E, **Caputi AP**, Cataldi S. Experimental investigation of 4-(trimethoxycinnamoyl)-1-piperaziny l-pyrrolidinyl maleate (67350): effect on the cardiovascular system and on certain smooth muscles. *Farmaco [Prat]*. 1973;28:132-60.
413. Marmo E, **Caputi AP**, Di Nola R, Cataldi S. [Salbutamol, an adrenergic stimulant drug acting mainly on beta-2-receptors: bibliographical review and experimental contribution] *Arch Monaldi*. 1973;28:83-178.
414. Marmo E, Saini RK, **Caputi AP**. Effects of various beta-adrenergic stimulant drugs on the serum cholinesterase levels of rats. *Res Commun Chem Pathol Pharmacol*. 1973;5:219-22.
415. Marmo E, Saini RK, Caputi AP. Properties of 1-isopropylamino-3-(4-indanoxy)-2-propanol (USVC 6524), an adrenergic -receptor blocking agent. *Farmaco [Prat]*. 1972; 27:661-87.
416. Marmo E, **Caputi AP**, Cataldi S. [Review of the literature and report of experiments relating to the coronaractive drug, hexobendine] *Minerva Cardioangiol*. 1972;20:571-81.
417. Marmo E, **Caputi AP**, Saini RK. [Review of literature and experimental contribution on KO 592 a drug with beta-adrenolytic activity. *J Clin Ter*. 1972; 62:117-63.
418. Marmo E, **Caputi AP**, Saini RK. [Review of literature and experimental contribution on KO 592, a drug with beta-adrenolytic activity. *J Clin Ter*. 1972; 62:11-51.
419. Marmo E, **Caputi AP**, Saini RK. New N-isopropyl and N-tert.-butyl- phenoxypropanolaminic derivatives having -adrenolytic, anti-arrhythmic and local anaesthetic activity.*Arzneimittelforschung*. 1972; 22:1109-17

420. **Caputi AP**, Marmo E, Saini RK. Pharmacology of a new beta-adrenoceptor blocking agent: the 15219. Res Commun Chem Pathol Pharmacol.1972; 4:25-35.

421. Marmo E, **Caputi AP**, Cataldi S. [The effect of the sulphonic ester of sodium adrenochrome semicarbazone and of adrenochrome semicarbazone on the cardiovascular system and intestinal musculature] Minerva Cardioangiol. 1972; 20:303-17.

422. Marmo E, **Caputi AP**. Analysis of the adrenergic effects of various drugs. Arch Int Pharmacodyn Ther. 1972; 196: 307.

### **Libri di cui sono autore**

1. Compendio di farmacologia generale e speciale  
Matilde Amico Roxas, Achille P. Caputi, Mario Del Tacca - Edra – 2021

2. Prescrizione off-label dei farmaci: Normative e applicazioni  
Achille P. Caputi, M. Rosa Luppino - SEEd – 2012

3. Drugs and laboratory parameters  
Achille P. Caputi, Guisepina Fava - SEEd – 2011

4. Le reazioni avverse a farmaci: sospetto e diagnosi.  
Achille P. Caputi, Fabrizio De Ponti, Luigi Pagliaro Raffaello Cortina Editore, 2009

5. Compendio di farmacologia generale e speciale  
Matilde Amico Roxas, Achille P. Caputi, Mario Del Tacca - Edra – 2007

6. Farmacologia in odontoiatria  
Matilde Amico Roxas, Achille P. Caputi, Mario Del Tacco - UTET – 2003

### **Capitoli in libri**

Numerosi sono i capitoli presenti in Libri di Farmacologia di altri coordinatori nonche in Libri Specialistici ed in Raccolte enciclopediche